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Summary 
Background: Prostate cancer is the most frequently diagnosed cancer in Canadian 
men and is the third deadliest after lung and colon cancers. Currently, prostate cancer 
treatments are based on results obtained of digital rectal exam, Gleason scores from biopsy 
specimens and serum PSA (Prostatic Specific Antigen) levels.  The identification of 
specific biomarkers for diagnosis and prognosis, as well as new therapeutic targets, is 
quickly paving the way for personalized medicine.  Ideally, in the future, patient care will 
include molecular signature of a patient's disease to guide for a more efficient treatment. 
  In this thesis, we evaluated the DNA damage response (DDR) as a potential 
biomarker in prostate cancer.  DNA lesions in mammalian cells trigger the DDR signalling 
cascade that orchestrates DNA repair and activate cell cycle checkpoints to preserve 
genome integrity.  Loss of genome stability is usually associated with cancer development, 
and activated DDR signalling in cells with genomic instability act as a cancer barrier in 
several pre-neoplastic human lesions, including prostate cancer.  Thus, the DDR is an 
important cancer suppression mechanism.  The DDR is also activated in response to anti-
cancer agents including radiation therapy (RT) and DNA-damaging chemotherapies.  Pre-
existing DDR levels in prostate cancer cells may influence the outcome of these cancer 
treatments.  DDR signalling has been detected during human prostate cancer progression 
from low levels in normal prostate cells to high levels in high-grade prostatic 
intraepithelial neoplasia (HG-PIN).  However, DDR signalling variations detected from 
HG-PIN to adenocarcinoma remain unclear, and no correlations were performed with 
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patient clinical outcome data.  Our hypothesis is that the levels of persistent DDR 
signalling activity will be variable with different grades and aggressiveness of prostate 
cancer. The levels of this activity could be correlated with the clinical responses to 
treatments and could even predict this process.  We believe that having new biomarkers 
will help personalizing cancer treatment and certainly increase treatments’ efficiency.   
Our objectives are to characterize the occurrence of DDR activation in prostate carcinoma 
and to correlate it with patients’ survival and responsiveness to treatment. 
  Methods: We used tissue microarrays (TMAs) from human radical prostatectomy 
specimens of 300 men with prostate cancer and estimated the level of DDR protein 
expression in the stromal and epithelial compartments of normal and aggressive cancer 
tissues.  The expression level of the DDR markers p53 binding protein-1 (53BP1), 
phosphorylated H2AX (p-H2AX), p65 (p65 subunit of Nuclear Factor (NF-κB) and 
phosphorylated checkpoint kinase-2 (p-CHK2) was quantified using immunofluorescence 
(IF) coupled to high-content automated imaging.  The quantification of our DDR markers 
was first validated on an experimental TMA (TMA-cell) including normal and irradiated 
(to induce DDR signalling) cultured human fibroblasts.  The data was quantified using 
binary layers commonly used to classify pixels in an image so areas could be analysed 
independently allowing the segregation of specific compartments including nuclei, 
epithelia and stroma.  Arithmetic operations were performed to render values 
corresponding to DDR activation that were then correlated with clinical outcomes such as 
biochemical recurrence and occurrence of bone metastasis.   
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 Results: We found that low levels of p65 protein expression in the nuclear epithelial 
compartments of normal prostate tissue were associated with a reduced probability of 
biochemical failure (which corresponds to a rise in the serum level of PSA in prostate 
cancer patients following treatment, surgery in this cohort of patients).  Moreover, we also 
observed that low levels of 53BP1 protein expression in the nuclear epithelial 
compartments of normal and cancerous prostate tissue were associated with a lower 
incidence of bone metastasis.   
 Conclusion: These results confirm that p65 has prognostic value in patients with 
prostate adenocarcinoma.  Based on our results, we suggest that 53BP1 marker may have a 
prognostic value as well.  The validation of other markers and particularly DDR markers 
may correlate with patients’ outcome.  With longer follow-up, it may translate into 
correlation with survival.  Levels of DDR activity in cancer tissue could be used in daily 
clinic as part of the patient’s diagnostic profile as much as his prostatic specific antigen 
(PSA) or Gleason score in order to predict response and personalize the treatment in order 
to guide the patients towards the most appropriate treatment amongst all those available for 
their prostate cancer.  	  
 
Keywords: DNA damage response (DDR), prostate cancer, DDR marker, biomarker. 
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Résumé 
Introduction: Au Canada, le cancer de la prostate est le cancer le plus fréquemment 
diagnostiqué chez les hommes et le plus mortel après les cancers du poumon et du côlon.  
Il y a place à optimiser le traitement du cancer de la prostate  de manière à mettre en œuvre 
une médecine personnalisée qui s’adapte aux caractéristiques de la maladie de chaque 
patient de façon individuelle. 
Dans ce mémoire, nous avons évalué la réponse aux dommages de l’ADN (RDA) comme 
biomarqueur potentiel du cancer de la prostate.  Les lésions potentiellement oncogènes de 
l'ADN déclenche une cascade de signalisation favorisant la réparation de l'ADN et 
l’activation des points de contrôle du cycle cellulaire pour préserver l’intégrité du génome.  
La RDA est un mécanisme central de suppression tumorale chez l’homme.  La RDA joue 
un rôle important dans l’arrêt de la prolifération des cellules dont les génomes sont 
compromis, et donc, prévient la progression du cancer en agissant comme une barrière.  
Cette réponse cellulaire détermine également comment les cellules normales et 
cancéreuses réagissent aux agents utilisés pour endommager l'ADN lors du traitement du 
cancer comme la radiothérapie ou la chimiothérapie, en plus la présence d,un certain 
niveau de RDA dans les cellules du cancer de la prostate peuvent également influer sur 
l'issue de ces traitements.  L’activation des signaux de la RDA peut agir comme un frein 
au cancer dans plusieurs lésions pré-néoplasiques de l'homme, y compris le cancer de la 
prostate.  Il a été démontré que la RDA est augmentée dans les cellules de néoplasie intra-
épithéliale (PIN) comparativement aux cellules prostatiques normales.  Toutefois, le 
devient de la RDA entre le PIN et l’adénocarcinome est encore mal documenté et aucune 
corrélation n'a été réalisée avec les données cliniques des patients.  Notre hypothèse est 
que les niveaux d’activation de la RDA seront variables selon les différents grades et 
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agressivité du cancer de la prostate.  Ces niveaux pourront être corrélés et possiblement 
prédire les réponses cliniques aux traitements des patients et aider à définir une stratégie 
plus efficace et de nouveaux biomarqueurs pour prédire les résultats du traitement et 
personnaliser les traitements en conséquence.  Nos objectifs sont de caractériser 
l'activation de la RDA dans le carcinome de la prostate et corréler ses données avec les 
résultats cliniques.  
Méthodes : Nous avons utilisé des micro-étalages de tissus (tissue microarrays-
TMAs) de 300 patients ayant subi une prostatectomie radicale pour un cancer de la 
prostate et déterminé le niveau d’expression de protéines de RDA dans le compartiment 
stromal et épithélial des tissus normaux et cancéreux.  Les niveaux d’expression de 53BP1, 
p-H2AX, p65 et p-CHK2 ont été quantifiés par immunofluorescence (IF) et par un logiciel 
automatisé.  Ces marqueurs de RDA ont d’abord été validés sur des TMAs-cellule 
constitués de cellules de fibroblastes normales ou irradiées (pour induire une activation du 
RDA).  Les données ont été quantifiées à l'aide de couches binaires couramment utilisées 
pour classer les pixels d'une image pour que l’analyse se fasse de manière indépendante 
permettant la détection de plusieurs régions morphologiques tels que le noyau, l'épithélium 
et le stroma.  Des opérations arithmétiques ont ensuite été réalisées pour obtenir des 
valeurs correspondant à l'activation de la RDA qui ont ensuite été corrélées à la récidive 
biochimique et l'apparition de métastases osseuses.   
Résultats : De faibles niveaux d'expression de la protéine p65 dans le compartiment 
nucléaire épithélial du tissu normal de la prostate sont associés à un faible risque de 
récidive biochimique.  Par ailleurs, nous avons aussi observé que de faibles niveaux 
d'expression de la protéine 53BP1 dans le compartiment nucléaire épithéliale du tissu 
prostatique normal et cancéreux ont été associés à une plus faible incidence de métastases 
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osseuses.   
Conclusion: Ces résultats confirment que p65 a une valeur pronostique chez les 
patients présentant un adénocarcinome de la prostate.  Ces résultats suggèrent également 
que le marqueur 53BP1 peut aussi avoir une valeur pronostique chez les patients avec le 
cancer de la prostate.  La validation d'autres marqueurs de RDA pourront également être 
corrélés aux résultats cliniques.  De plus, avec un suivi des patients plus long, il se peut 
que ces résultats se traduisent  par une corrélation avec la survie.  Les niveaux d'activité de 
la RDA pourront éventuellement être utilisés en clinique dans le cadre du profil du patient 
comme le sont actuellement l’antigène prostatique spécifique (APS) ou le Gleason afin de 
personnaliser le traitement. 
 
 
Mots clés:  Réponse aux dommages de l’ADN (RDA), Cancer de la prostate, Marqueur 
de RDA, Biomarqueur	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CHAPTER 1: INTRODUCTION 
1.0 Prostate Cancer 
1.1 Overview of prostate cancer 
Prostate cancer is the most frequently diagnosed cancer in Canadian men and is the 
third deadliest cancer in males after lung and colon cancer 1.   
According to the Canadian Cancer Society, Canadian males are most likely to develop 
prostate cancer, with one in eight males expected to be diagnosed with prostate cancer 
in their lifetime (statistics Canada website: http://www.cancer.ca/en/cancer-
information/cancer-101/canadian-cancer-statistics-publication/?region=qc).   
More than 23 000 new cases of prostate cancer were diagnosed in Canada in 2013 with 
almost 5000 of these being in the province of Quebec.  High-grade prostatic 
intraepithelial neoplasia (HG-PIN) is considered the precursor of prostate carcinoma.  
It is associated with progressive abnormalities of phenotype and genotype, which are 
midway between normal epithelial cells and cancer cells.  This indicates impairment of 
cell differentiation and regulatory control with advancing stages of prostatic 
carcinogenesis 2.  
Management of localized non-metastatic prostate cancer remains very complex 
because there are multiple issues to consider including risk stratification, efficacy and 
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toxicity of the different treatments, relative risk of death from diseases other than the 
cancer itself and lastly, patient preferences 3.  The National Comprehensive Cancer 
Network (NCCN), an alliance of the world's leading cancer centers, is an authoritative 
source of comprehensive cancer, which develops guidelines to improve the quality, 
effectiveness and efficiency of cancer care.  Both the National Comprehensive Cancer 
Network (NCCN) risk classification and the D’Amico classification, which are very 
similar, are the most commonly used categorical strategies for pre-treatment risk 
estimation in prostate cancer.  Originally developed in 1998 by a medical researcher 
named D’amico, this classification system is designed to evaluate the risk of recurrence 
following localized treatment of prostate cancer.  It stratifies patients in three 
categories based on three parameters: 
a) Patient’s diagnostic serum prostatic specific antigen (PSA): The PSA is a protein 
made by the cells of the prostate gland.  It is mostly found in semen, but it is also 
normal to find small amounts of PSA in the blood of healthy men.  In case of prostate 
cancer, PSA levels are often above normal as it is secreted in excess by the prostate 
cancer cells. 
b) Patient’s highest biopsy Gleason score: The Gleason score is given to prostate 
cancer based upon its microscopic appearance.  Lower grades are associated with small, 
closely packed glands.  Cells spread out and lose glandular architecture as grade 
increases.  Gleason score usually varies between 6-10 with 10 being the highest 
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possible grade. 
c) Patient’s clinical stage:  The clinical stage varies from T1 to T4 and is determined by 
the physician’s digital rectal exam of the prostate gland.  Indeed, the prostate can be 
palpated through the rectum.  T1 represents the absence of a palpable tumor whereas 
T4 represents a tumor invading the bladder or rectum. 
 
Low Risk 
Diagnostic PSA < 10.0 ng/mL and 
Highest biopsy Gleason score ≤ 6 and 
Clinical stage T1c or T2a 
Intermediate Risk 
Diagnostic PSA ≥ 10 but < 20 ng/mL or 
Highest biopsy Gleason score = 7 or 
Clinical stage T2b 
High Risk 
Diagnostic PSA ≥ 20 ng/mL or 
Highest biopsy Gleason score ≥ 8 or 
Clinical stage T2c/T3 
 
 
 
Table 1: D’Amico risk stratification for clinically localized 
prostate cancer 
This risk stratification is based on clinical characteristics such as the diagnostic serum PSA, the Gleason 
score as determined by the pathologist from prostate biopsy and the clinical stage as determined by the 
physician’s digital rectal exam. 
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Nomograms are online tools that have been developed to guide and help clinicians 
decide which treatment approach (ie: surgery, radiation therapy (RT) or androgen 
deprivation therapy - ADT) can be offered to a patient.  The nomogram analysis is 
based on multiple factors such as PSA values and number of positive biopsy cores. 
Nomograms are often complex, time-consuming (making routine use difficult), and are 
not necessarily applicable to individual treating centers 4.  An important advantage of 
risk grouping systems (ie: D’Amico or NCCN classifications) compared to nomograms 
is their simplicity 5.  On the other hand, risk groups have the disadvantage of assuming 
that patients within the same group are homogeneous.  Moreover, risk groups do not 
consider factors such as the number of positive biopsies or whether there are single or 
multiple intermediate-risk or high-risk factors present when considering the treatment 
decisions.  Nomograms do incorporate this information, but more time is required to 
calculate the score and this information may not be applicable for use in daily clinical 
practice.  Regardless of the scoring system, which is used by the clinician in his/her 
practice, neither the risk classification nor the nomograms incorporate the tumor’s 
biology.  The most important criterion for a prediction tool is its ability to discriminate 
between patients with or without a given outcome with high accuracy 6.  Predictive 
models for patients treated by RT for localized prostate cancer have been established 7.  
Recently, the Genito-Urinary Radiation Oncologists of Canada (GUROC) developed a 
pan-Canadian Prostate Cancer Risk Stratification (ProCaRS) database based on 7974 
patients and this group of experts suggests that the definition of additional risk 
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categories (i.e., very low risk and very high risk) may further improve patient risk 
categorization8.  A recent trial (PIVOT trial) where patients with clinically localized 
prostate cancer were randomized between radical prostatectomy and active surveillance 
(ie: no treatment) showed that active surveillance remains an excellent option for 70% 
of patients diagnosed with low risk prostate cancer9.   However, 90% of diagnosed 
patients still favour treatment because of the anxiety associated with an untreated 
cancer.  Prostate cancer treatments include surgery to remove the prostate gland 
(radical prostatectomy (RP)), external beam radiation (EBRT), interstitial 
brachytherapy (low dose rate - LDR and high dose rate - HDR), ADT or a combination 
of these therapies.  Each treatment comes with its  own set of side effects, which are 
not negligible.  Nevertheless, to date, clinicians do not have the necessary tools 
(markers) to identify men with slow growing cancers (that can be managed by active 
surveillance) from men with aggressive cancers (that require treatment).  As such, until 
we establish better predictive models, clinicians will continue to rely on basic risk 
classification systems that typically incorporate information on DRE (digital rectal 
exam), serum PSA and pathology from biopsy specimens (Gleason score-GS).  
 	   6	  
 
 
 
1.2 Cellular effects of radiation therapy 
Radiation therapy (RT) is administered by one of several methods.  It can be given via 
an external source using a linear accelerator, which is directed toward the tumor 
(almost always by intensity modulated radiation therapy (IMRT) in order to protect 
healthy tissues).  Alternatively, RT can be given by an internal source (e.g. 
brachytherapy where radioactive sources such as Iodine 125 are placed and decay 
Figure 1: Gleason grading system diagram 
This figure illustrates a cartoon (left panel) as well as histological (right panel) representation of 
cells according to the Gleason grade (1-5).  The number is assigned to two of the areas of the 
prostate that have the most cancer on the biopsy cores taken.  Those two numbers are added 
together to come up with the Gleason score, which ranges from 2 to 10.  
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within the tumor).  Radiation interacts with matter by the photoelectric effect, the 
coherent scattering effect, the pair production effect, the photodisintegration or the 
Compton effect.  The latter is the most relevant for the range of energies used in 
clinical RT.  In the Compton effect, the observed biologic effect results from photons 
creating multiple ionizations by ejection of electrons from the target biomolecule 10.  In 
this regard, the extent of biologic effects in cells after exposure to ionized radiation is 
largely due to oxygen with the subsequent production of free radicals.  These free 
radicals can break cellular deoxyribonucleic acid (DNA), which is the critical target for 
the biologic effects of ionizing radiation.  The extent of DNA damage will eventually 
determine cell death 11; 12.  Cells that cannot effectively repair their DNA damage are 
therefore more sensitive to ionizing radiation 13.  It is also known that when radiation is 
focused on the nucleus rather than on the cytoplasm, cell death occurs at a higher      
rate 14.  Interference to DNA can occur directly or indirectly, but mostly via indirect 
means in that photons of radiation being more likely to ionize the molecules 
surrounding the DNA creating free radicals, which subsequently destabilize nucleic 
acids 15; 16.  Cells that are unable to generate free radicals (cells under hypoxic 
conditions) are much less sensitive to ionizing radiation compared to those that are well 
oxygenated.  This explains why the effect of radiation is related with blood flow and 
oxygen concentration of the target tissue 17. 
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2.0 The DNA damage response (DDR)  
2.1 DNA damage 
In human cells, both normal metabolic activities and environmental factors such as 
ultraviolet (UV) light and radiation can cause DNA damage, resulting in as many as 1 
million individual molecular lesions per cell per day.  Many of these lesions cause 
structural damage to the DNA molecule and can alter or eliminate the cell's ability to 
transcribe the gene that the affected DNA encodes.  Other lesions induce potentially 
harmful mutations in the cell's genome, which affect the survival of its daughter cells 
after it undergoes mitosis.  Therefore, if these lesions are not or are incorrectly repaired, 
they lead to mutations or aberrations that threaten viability.  DNA damage leading to 
either single strand break (SSB), impair base pairing and/or DNA replication or 
transcription errors may be produced by 18:  
a) Physiological processes (ex: DNA mismatches introduced during DNA 
replication) 
b) Hydrolytic reactions and non-enzymatic methylations 
c) Abortive topoisomerase I and II activity 
d) Reactive-oxygen compounds (ex: arising either from oxidative respiration or 
produced by macrophages and neutrophils at sites of infections and 
inflammation). 
 	   9	  
Double-strand breaks (DSB), although not as frequent as SSB, impair base pairing and 
DNA replication or transcription errors, are difficult to repair and are very lethal.  
DSBs can arise from a) two single strand breaks that are in close proximity b) ionizing 
radiation or c) from treatment using chemical drugs such as certain chemotherapy 
agents.  Because of the importance of DNA, cells have developed a complex series of 
processes and pathways to ensure that the DNA remains undamaged and unaltered 
despite the continuous attack from the inside (ex: oxidation and alkylation owing to 
metabolism) as well as from the outside (ex: ingested chemicals, ultraviolet (UV) and 
ionizing radiation) 19.  These include multiple types of DNA repair aimed at repairing 
various types of DNA damage caused by a variety of agents.   
Specialized repair systems have therefore evolved for detecting and repairing damage: 
a) to bases: The Base Excision Repair (BER), where most of the damaged bases in the 
DNA will be detected and removed by specialized proteins called glycosylases.  They 
cut out the damaged base without cutting the DNA backbone, resulting in an abasic site. 
Another class of enzyme (endonucleases) will recognize this and will cut the DNA 
backbone leaving a SSB.  The resulting SSB can then be processed by either short-
patch (where a single nucleotide is replaced) or long-patch BER (where 2-10 new 
nucleotides are synthesized) 20.  Ligases will then seal the break. 
b) To single-strand breaks: The Single strand break repair (SSBR) which is similar to 
BER but since radiation itself causes the break rather than being a repair intermediate, 
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the ends are not recognized by ligases.  There is therefore an extra end-processing step, 
mainly by the enzyme polynucleotide kinase (PNK).  Once a clean nick is produced, 
short or long patch repair can then follow as for BER. 
 c) To double-strand breaks (Homologous recombination (HR) and Non-homologous 
end joining (NHEJ)).  These two repair mechanisms are quite different in the genes 
involved, the position in the cell cycle where they primarily act and in the speed and 
accuracy of repair.  These processes are described in more detail below.  
All these lesions are produced by ionizing radiation.  There are also other DNA repair 
pathways, such as those for correcting mismatches of bases in DNA which can occur 
during replication, such as mismatch repair (MMR), and for repairing bulky lesions or 
DNA adducts such as those formed by UV light and some drugs such as the 
chemotherapeutic agent cisplatin (NER-Nucleotide Excision Repair). 
The DNA damage response (DDR) is a highly complex and coordinated system that 
determines the cellular outcome of DNA damage.  This system can be divided in two 
parts, the sensors of DNA damage and the effectors of the damage response. The 
sensors consist of a group of proteins that actively examine the genome for the 
presence of the damage.  These proteins then signal this damage to three main effector 
pathways that together determine the outcome for the cell.  These effector pathways 
include (1) programmed cell death pathways that destroy damaged cells, (2) DNA 
repair pathways that physically repair DNA breaks and (3) pathways that cause 
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temporary or permanent halts in the progress of cells through the cell cycle--the 
damage checkpoints.  
Failure of the DDR or associated events causes genomic instability, an underlying 
cause of several human syndromes and diseases, particularly cancer.  
  
2.2 Cellular detection of DNA damage 
Shortly after exposure to ionizing radiation, a signal is transmitted to the regulators of 
the cell cycle machinery and the sensors of DNA damage.  Cells with damaged DNA 
mostly undergo G1 or G2/M cell cycle arrest.  During this cell cycle arrest, normal 
cells can either 1) repair and continue through the cell cycle, 2) not repair and stay 
arrested, or 3) not repair and undergo apoptosis 21.  Cells have developed mechanisms 
that sense the presence of the DSBs and initiate the DDR.  The DDR is essential to stop 
the proliferation of cells with genomic instability, and therefore, prevent events that 
can contribute to cancer initiation and progression.   
The first cellular response to DSBs is characterized by the recruitment of many 
different proteins to the sites of DNA damage.  This clustering (known as foci) can be 
observed microscopically as small regions or dots in the nucleus following staining 
with antibodies to these proteins (See Chapter 2, figure 1).  One of the earliest events to 
occur in the DDR (occurring within 5-30 minutes after induction of a DSB) is the 
phosphorylation of the protein called histone H2AX 22.  This phosphorylated form 
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(known as γ-H2AX or p-H2AX) is required for the recruitment of many of the other 
proteins involved in the DDR.  The early phosphorylation of H2AX indicates that one 
or more kinases are activated at the sites of DSBs.  Three related kinases have been 
shown to be able to phosphorylate H2AX at sites of DSBs 23:  
(1) ATM-MRN 
(2) DNA-PKcs-KU 
(3) ATR-ATRIP   
 
2.2.1 ATM-MRN 
The phosphorylation of H2AX occurs primarily by the protein ATM (Ataxia 
Telangiectasia Mutated).  ATM is normally present in the cell, but in an inactive form.  
Activation of ATM occurs once it becomes associated with a DSB resulting in 
phosphorylation of H2AX at the site of the DSB.  However, in order to detect and 
locate the DSB and be activated, ATM requires at least one additional protein complex.   
This complex is known as MRN.  The MRN complex consists of the proteins Mre11, 
Rad50, and Nbs1 24, 25, 26  . This MRN complex is able to recognize damaged DNA and 
bind to or near the site and transmit DDR signals downstream to the transducers, which 
is important for the ‘’processing’’ of the DSB. These transducers are members of the 
phosphoinositide 3-kinase related kinase (PIKK) family such as ATM and ATR (ATM 
and Rad 3-related) 24, respectively.  Moreover, one of the key functions of Nbs1 is to 
 	   13	  
directly bind to ATM, and bring it to the site of damage and Rad50 directly binds to 
DNA.   
 
2.2.2 DNA-PKcs-KU 
DNA-dependent protein kinase (DNA-PKcs) is a kinase that is structurally related to 
ATM and which is very important in the NHEJ DNA repair.  The mechanism through 
which it finds DSBs is very similar to that of ATM.  Like ATM, DNA-PKcs is unable 
to act as a sensor of damage itself.  This sensor function is carried out by the Ku70-
Ku80 complex, which directly binds to the ends of DSBs.  This binding then recruits 
DNA-PKcs allowing phosphorylation of H2AX. 
 
2.2.3 ATR-ATRIP 
AT-related kinase (ATR) does not a prominent role in the initial recognition of the 
DSBs but is important for the types of damage that occur during normal DNA 
replication.  ATR phosphorylates H2AX in response to other types of DNA damage 
and abnormalities such as stalled or broken replication forks and single-stranded DNA. 
Just like ATM and DNA-PKcs, ATR is recruited to sites of damage by ATRIP (ATR 
interacting protein) that acts as the sensor of the damage.  As described above, the 
ATM-MRN complex leads to processing of the DNA at sites of DSBs.  This can create 
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stretches of single-stranded DNA, which will then activate ATR.  Thus, ATR can be 
activated downstream of ATM which then phosphorylates a distinct set of proteins that 
participate in the DDR. 
ATM and ATR are key components of these initial sensors of DNA damage 27; 28.   
While ATR is only activated when DNA is being replicated in S phase, ATM can be 
activated throughout the cell cycle. 
Finally, although ATM and ATR have some overlapping activities, they are activated 
by separate signals and by different types of DNA damage 29; 30.  
 
  2.3   Signalling to effector pathways 
Activation of ATM, DNA-PKcs and ATR leads to the phosphorylation not only of 
H2AX, but also of many other cellular proteins. It has been shown that as many as 700 
proteins are substrates for the ATM and ATR kinases in response to DNA damage 31.  
They relay the signal to various downstream effectors that mediate cell cycle arrest, 
DNA repair, and apoptosis.   
ATM substrates include H2AX and 53BP1, which facilitates checkpoint activation and 
repair, both essential for their efficient repair of DNA damage.  Phosphorylated H2AX 
and 53BP1 rapidly localize to DSBs, forming characteristic foci.  ATM also 
phosphorylates the kinase CHK2 (p-CHK2), which promotes growth arrest and p53, a 
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tumor suppressor and transcriptional regulator that coordinates repair and cell cycle 
arrest 32.  This DDR leads to transient cell cycle arrest and DNA repair, cell death, or 
permanent cell cycle arrest (cellular senescence) preventing cells to replicate with 
accumulated mutations thereby protecting cellular integrity and avoiding the 
development of cancers 33; 34.  Figure 2 35 illustrates in a cartoon fashion the major 
DDR activation pathways.  DNA damage sensors (MRN and ATRIP complexes) detect 
DNA damage and then recruit ATM and ATR, respectively.  These, in turn, 
phosphorylate (P) the histone variant H2AX on Serine 139 (γ-H2AX) in the region 
proximal to the DNA lesion.   
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Figure 2: Major DDR Activation pathways  
MRN and ATRIP complexes detect DNA damage, which then recruit ATM and ATR, respectively.  
These in turn phosphorylate (P) the histone variant H2AX on Serine 139 (γ-H2AX) in the region 
proximal to the DNA lesion.  γ-H2AX is required to recruit mediator of DNA damage checkpoint 1 
(MDC1) that further maintains and amplifies DDR signalling by enforcing additional accumulation of the 
MRN complex and activation of ATM.  
Sulli G, Di Micco R, d’Adda di Fagagna F. Crosstalk between chromatin state and DNA damage response in cellular 
senescence and cancer.  Nature reviews.  Cancer.  Oct 2012;12(10):709-720.  Written authorization obtained by Dr 
Fabrizion d’Adda di Fagagna, Principal Investigator IFOM Foundation – The FIRC Institute of Molecular Oncology 
Foundation on April 10th 2014. 
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As mentioned previously, 53BP1 is also involved in sustaining DDR signalling by 
enhancing ATM activation.  DDR signalling relies on additional mechanisms that are 
based on ubiquitination (a post-translational modification where ubiquitin is attached to 
a substrate protein).  This post-translational modification affects proteins in many ways.    
It can be a signal for (1) protein degradation (via the proteasome), (2) change in 
cellular location, (3) change in protein activity and (4) change in protein-protein 
interactions.  In DDR, γ-H2AX is ubiquitylated by ring finger protein 2 (RNF2), which 
causes the recruitment of Polycomb complex protein BMI-1 (B lymphoma Mo-MLV 
insertion region 1 homolog) to sites of DNA lesions.  BMI1 is an oncogene which 
blocks transcriptional elongation at the DNA damage site and promotes DNA        
repair 35; 36. 
Eventually, DDR signalling spreads away from the region of the damaged DNA and 
triggers the diffusible kinases CHK2 (which is mainly phosphorylated by ATM) and 
CHK1 (which is mainly phosphorylated by ATR) with signalling converging on 
downstream effectors such as p53 and the cell division cycle 25 (CDC25) phosphatases.  
 
2.4 DDR and ionizing radiation 
In order for a cell to synthesize its DNA and go through division, it needs to pass by 
the multiple cell cycle checkpoints.  Blocks at these checkpoints can prevent important 
cell cycle transitions to ensure the integrity of the DNA 37; 38; 39; 40.  All movement 
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through the cell cycle, be it in the G1, S, G2 or M phases, is driven by cyclin-
dependent kinases (CDKs).  The CDKs phosphorylate other proteins to initiate the 
processes required for progression through the cell cycle.  
Depending on when the cell is exposed to radiation in its cell cycle, it may respond 
differently.  Cells are extremely sensitive to radiation during mitosis (during which 
there is little DNA repair) 41; 42; 43; 44.  DNA damage can activate multiple pathways that 
eventually lead to G1 arrest.  When ATM is activated, it stabilizes p53 by 
phosphorylating its serine-15 and also adds a phosphate group on serine 395 of mouse 
double minute 2 homolog (MDM2).  Phosphorylation of MDM2 prevents p53-MDM2 
nuclear export and degradation of p53 45.  As mentioned in the previous section, ATM 
is also known to phosphorylate Chk2, which subsequently phosphorylates p53 on 
serine 20 46.  This further prevents interaction of p53 and MDM2 and hence increases 
levels of available nuclear p53, which is free to transcriptionally activate p21, a major 
inhibitor of the cyclin E- Cyclin-dependent kinase 2 (CDK2) complex 47.   
ATM also controls a p53/p21 independent G1 arrest pathway.  When ATM activates 
Chk2, it phosphorylates cdc25A, which is primed for ubiquination and subsequent 
degradation 48.  Cdc25A is a phosphatase that removes inhibitory phosphates from 
CDK2 and CDK4, both of which are important G1 phase progression molecules 24.   
Cells have been shown to be radioresistant during the G1 phase, but their 
radiosensitivity increases at the end of this phase 49 .  Most commonly, irradiated cells 
can be blocked in the G2/M phase, which is the next most sensitive phase in the cell 
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cycle post replication.  Although the G2/M checkpoint remains complex and is not 
fully understood, there are multiple known pathways involved in this arrest 24.  The 
final step in this pathway is deactivation of the cyclin B- Cyclin-dependent kinase 1 
(CDK1) complex, which orchestrates the G2/M transition 50.  The specific site of 
phosphorylation determines activation or deactivation of the CDK1 complex. The 
ATM/CDC25A pathway is also important because cdc25A is an activator of the cyclin 
B-CDK1 complex.  ATM activates p21 (through p53), which is an inhibitor of an 
activator of CDK1, namely CAK (CDK activating kinase) 51.   
 
2.5   DNA repair 
As seen above, once cells are irradiated, they sense the DNA damage and eventually 
activate the mechanism for DNA repair.  Various repair processes are activated 
according to the lesion types, with DSBs being the most lethal lesion to the cell 
compared to single-strand breaks.  These lesions can be repaired either through 
homologous recombination (HR) or non-homologous end-joining (NHEJ) 52.  In the 
former, either the intact chromosome or the sister chromatid serve as a template to 
reconstruct the missing DNA.  HR is most effective in late S or G2 phase, when the 
sister chromatids have replicated but are still attached 53.  NHEJ is more important in 
G1 and early S phase, but can essentially occur throughout the cell cycle 52.  Once cells 
are irradiated, ATM phosphorylates histone H2AX resulting in quick localized 
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accumulation of the protein 53BP1.  This protein is involved in enhancing 
phosphorylation of the tumor suppressor molecule p53, activating proteins essential for 
DNA repair, and inducing G2 checkpoint block 54; 55; 56.  Thus, G2 checkpoint induced 
by radiation, possibly via 53BP1, provide more time for repair and increases the 
probability of escaping cell death.  
 
2.6 Nuclear factor-kappa B (NF-κB) transcription factors 
Our group has already addressed the prognostic value of the p65 subunit of NF-κB in 
prostate cancer (p65) where it was observed that elevated amounts of nuclear p65 in 
tumors is associated with more aggressive prostate cancer 57; 58; 59.   
The NF-κB family is composed of five transcription factors characterized by their Rel-
homology domain responsible for DNA binding, dimerization and interaction with 
inhibitor of κB (IkB) proteins.  The family is subdivided into two groups, members of 
the first group named RelA (p65), RelB, and c-Rel, carry a transactivation domain 
responsible for NF-κB potent activity as a transcription factor.  The second group 
contain NFκB1 (p50 and its precursor p105) and NFκB2 (p52 and its precursor p100).  
The carboxy-terminal domain of p105 and p100 contains ankyrin repeats that must be 
degraded to create transcriptionally active p50 and p52 proteins respectively.  All these 
transcription factors function as homo and heterodimers, the dimer most known and 
studied is composed of subunits p50 and RelA (p65).  In most normal cells, the dimer 
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p50-p65 is kept inactive in the cytoplasm by association with IκB family of inhibitors 
(α and β) 60;61.   
Research from the past 20 years has revealed that there are three major NF-κB 
pathways can be distinguished 62;63;64.  The first is the classical or canonical pathway in 
which p65/p50, the main active dimer, is rendered inactive by IκB inhibitors (IκBα and 
IκBβ).  This pathway may be activated by signals such as the proinflammatory 
cytokine tumor necrosis factor α (TNFα).  The activation of NF-κB also often requires 
the activation of the IKB-Kinase complex (IKKα, IKKβ and IKKγ) via multiple signals 
including (but not limited to) cytokine binding to cell surface receptors, DNA damage, 
hypoxic conditions, and oxidative stress 65.  Canonical NF-κB signaling is induced 
rapidly within minutes of stimulation without the need for de novo protein synthesis.  
The alternative or non-canonical pathway is activated by a smaller number of inducers, 
such as lymphotoxin β and B cell activating factor, and plays an important role in B-
cell maturation and the formation of secondary lymphoid tissues 66;67.  This pathway 
uses RelB/p52 as the active dimer.  
In the canonical pathway (IKKβ-dependent), the IKK complex phosphorylates IKBs 
that are then ubiquitinated and degraded by proteasomes. In the non-canonical pathway 
(IKKα-dependent), the IKK complex regulates the processing of the p100 precursor.  
Subsequently, the NF-κB complex translocates to the nucleus and activates the 
expression of specific target genes 68;69.  Although p65/p50 represents the main 
functional unit of the classical NF-κB pathway, p65 also forms transcriptionally active 
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dimers with p52.  In the same way, RelB/p52 constitutes the main alternative 
functional unit, however, RelB can also dimerize with p50 resulting in another 
alternative NF-κB functional unit 70. 
Finally, and particularly relevant to our study, the third NF-κB pathway, the so-called 
‘atypical pathways’, refer to those pathways that do not fall in the abovementioned 
categories.  Originally, all signaling cascades activated by atypical stimuli, such as 
DNA damage or oxygen stress, were classified as ‘atypical’ NF-κB activators, as they 
all induce a slow and weak NF-κB signal (with peak activities reached after 2–4 h).  
Later studies revealed that these stimuli could not be categorized in one class as they 
induced completely unrelated pathways.  Thus, ultraviolet (UV)-induced NF-κB 
signaling appears to occur in an IKK-independent way, while most other genotoxic 
stress agents activate a pathway that follows more or less the classical NF-κB 
activation scheme.  For example, ionizing radiation (IR)-induced NF-κB activation has 
been reported following both low and high doses of irradiation71;72.  This NF-κB 
activation results in the induction of anti-apoptotic genes, inhibiting apoptosis induced 
by many chemotherapeutic drugs and irradiation 73;74;75;76.  Similarly, NF-κB activation 
impact numerous other molecular and biological functions that could be relevant for 
responses to chemo-radiation such as inflammation 77;78, angiogenesis 79, survival, 
migration, and invasion 80 are associated with the activity of NF-κB nuclear factors.   
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ATM and NF-κB 
Given the nature of the biological processes modulated by NF-κB, it is not surprising 
to see an overactivation of NF-κB in many cancers 81.  Regarding solid tumors, aber-
cant nuclear localization of subunits of NF-κB has been observed in various cancers, 
including pancreatic 82, breast 83, endometrium 84, renal 85 and melanoma 86.  Moreover, 
a large number of cell lines exhibiting high activity of the dimer p50-p65 are resistant 
to various chemotherapeutic agents 76; 87. 
Furthermore, genotoxic agents used in cancer treatment (ex: IR, chemotherapy such as 
topoisomerase inhibitors, replication stress inducers such as hydroxyurea or DNA 
photolesions induced by UV-C) can activate p50/RelA NF-κB complexes through the 
atypical pathway or through activation of CK2 (formally known as casein kinase II).  
CK2 is a highly conserved and ubiquitous serine/threonine kinase that may participate 
in the transduction of survival signals 88;89 and CK2-mediated IκBα phosphorylation 
has an important UV-protective function 90.  Recently, several studies have shown that 
ATM is essential for NF-κB activation following DNA damage 91;92;93;94;95.  
The ATM-NEMO (Nf-κB essential modulator) pathway activates p50/RELA Nf-κB 
complexes via the induction of IKKβ following DNA damage 96;95.  Following cellular 
stresses, the nuclear translocation of the RIP1/NEMO death domain complex occurs.  
This nuclear NEMO is then post-transcriptionally modified by the small ubiquitin-like 
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modifier (SUMO)1, and phosphorylated by ATM, which is simultaneously activated in 
case of DNA damage.  Ubiquitination of the ATM–NEMO complex targets these 
proteins for nuclear export, enabling the complex to interact with and activate the IKK-
β subunit and initiate IkB-α phosphorylation 97;95;91.  This is substantiated by the 
discovery that the ATM inhibitor KU55933 block both constitutive and DNA damage-
activated NF-κB in breast cancer cell lines with mutant p53 and the downstream 
inhibition of NF-κB activation is a major mechanism accounting for the radio-
sensitizing effect of this ATM inhibitor98.   
Unlike NF-κB signaling induced by cell surface receptors where the signal initiation 
event can be precisely defined, the necessary and sufficient molecular signal initiation 
events induced by various genotoxic agents are still being addressed.  Highlighting the 
complexity of this issue, ultraviolet (UV) irradiation-induced NF-κB activation led to 
the conceptualization of nuclear-to-cytoplasmic signalling99.  Accumulated evidence 
over the last two decades demonstrates that nuclear DNA damage is probably not the 
signal initiation event for immediate activation of NF-κB in this case 100;101;102.  
Importantly, several lines of evidence support the requirement of nuclear DSB in 
initiating the canonical IKK-NF-κB signaling pathway in response to many different 
genotoxic agents 96;103. 
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Figure 2 A model depicting distinct and common steps between NF-κB signaling induced by TNFα and DNA damaging 
agents. TNFα stimulation of TNFR1 engages receptor adaptor proteins (TRADD and RIP1) and results in the recruitment of 
ubiquitin conjugating enzymes (Ubc13/Uev1A and UbcH5) and E3 ligases (cIAP1/2, TRAF2/5 and HOIL/HOIP) to promote 
K63-linked, mixed and linear polyubiquitination of multiple target proteins. These polyubiquitin chains form the scaffold 
on which TAK1/TAB2/3 and IKK/NEMO complexes are formed and TAK1-dependent activation of IKKβ is induced. DNA 
damaging agents, such as etoposide, cause ATM activation via induction of DSB and SUMOylation of NEMO through a 
mechanism dependent on PARP1, PIASy and Ubc9. PIASy dependent SUMOylation of NEMO may also be induced by ad-
ditional stress conditions. ATM then phosphorylates NEMO, which results in cIAP1-dependent monoubiquitination of NEMO. 
ATM and NEMO are exported to the cytoplasm where K63-linked polyubiquitination of ELKS and TRAF6 via ATM-dependent 
mechanism, as well as monoubiquitination of NEMO on lysine 285 via cIAP1, are induced. The polyubiquitin scaffolds 
then activate IKK via TAK1, similar to the mechanism induced by TNFα.  Active   IKK   then  phosphorylates   IκBα, which then 
causes  K48-­linked  polyubiquitination  and  degradation  of   IκBα by the proteasome to liberate active NF-κB (p50/p65) dimer. 
Polyubiquitin is represented in repeated yellow units, phosphate is shown in orange oval with “P” and SUMOylation is shown 
in purple circle with “S”. LUBAC, linear ubiquitin assembling complex. 
Miyamoto S., Nuclear initiated NF-κB signaling: NEMO and ATM take 
center stage, Cell Res, 21, 116-30, 2011. Written authorization obtained by 
Dr Miyamoto and the journal through Copyright Clearance Center's 
RightsLink ervi e 
Figure 3:  A model depict g distinct and ommon steps between 
NF-κB signalling induced by TNFα and DNA damaging agents 
In this figure 3, one can see that TNFα stimulation of TNFR1 engages receptor adaptor proteins 
(TRADD and RIP1) and results in the recruitment of ubiquitin conjugating enzymes 
(Ubc13/Uev1A and UbcH5) and E3 ligases (cIAP1/2, TRAF2/5 and HOIL/HOIP) to promote 
K63-linked, mixed and linear polyubiquitination of multiple target proteins. These polyubiquitin 
chains form the scaffold on which TAK1/TAB2/3 and IKK/NEMO complexes are formed and 
TAK1-dependent activation of IKKβ is induced.  DNA damaging agents, such as etoposide, a 
widely used chemotherapeutic drug, cause ATM activation via induction of DSB and 
SUMOylation of NEMO through a mechanism dependent on PARP1, PIASy and Ubc9. PIASy 
dependent SUMOylation of NEMO may also be induced by additional stress conditions. ATM 
then phosphorylates NEMO, which results in cIAP1-dependent monoubiquitination of NEMO. 
ATM and NEMO are exported to the cytoplasm where K63-linked polyubiquitination of ELKS 
and TRAF6 via ATM-dependent mechanism, as well as monoubiquitination of NEMO on lysine 
285 via cIAP1, are induced. The polyubiquitin scaffolds then activate IKK via TAK1, similar to 
the mechanism induced by TNFα.  Active  IKK  then  phosphorylates  IκBα, which then 
causes  K48-linked  polyubiquitination  and  degradation  of  IκBα by the proteasome to liberate 
active NF-κB (p50/p65) dimer. Polyubiquitin is represented in repeated yellow units, phosphate is 
shown in orange oval with “P” and SUMOylation is shown in purple circle with “S”.       
(LUBAC, linear ubiquitin assembling complex). 
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2.7 DDR as a barrier to cancer progression 
The DDR acts as a barrier against the progression of cancer beyond its early stages. 
Previous research in animal models has shown that activation of numerous oncogenes 
or loss of tumor suppressors result in DNA replication stress or DNA damage.       
DNA damage triggers the DDR, which leads to cellular senescence or death of 
oncogene-transformed cells and results in delay or prevention of tumor formation.  
Recent discoveries reinforce this dogma and demonstrate that activated DDR signalling 
act as a cancer barrier in several pre-neoplastic human lesions, including prostate 
cancer 104; 105.   
A Canadian group has analyzed 35 primary prostate cancer specimens for ATM 
activation, p-CHK2, p-H2AX and p53 by immunohistochemistry in normal prostate 
glands, PINs (the precursors to carcinomas) and carcinomas104.  They had showed an 
increased intensity of p-ATM, p-CHK2 and p-H2AX in PINs, compared to normal 
prostatic glands or carcinomas.  Figure 4 depicts representative images of the detected 
levels of ATM activation in normal prostatic glands and carcinoma compared to PINs.  
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These findings suggest that early oncogenic events result in ATM activation, that are 
attenuated by events occurring in the later stages of prostate tumorigenesis, perhaps via 
genome re-stabilization in advanced cancer cells.  The authors mention that the 
activation of ATM at the early stages of prostate tumorigenesis prevents tumor 
progression and its desensitization to oncogenic signals promotes tumor development.  
However, little is known about DDR activity beyond the PIN stage.  Of note this study 
Figure 4: ATM activation in normal prostatic gland, PIN, and carcinoma 
 
ATM activation in normal prostatic gland, PIN, and carcinoma: Morphologically normal prostatic gland, PIN, and 
carcinoma from the same patient (or slide) were H&E stained and immunohistochemically stained for Ser1981 
phosphorylated ATM using an anti-pSer1981-ATM antibody. The inset areas are enlarged (right column). 
 
Fan C, Quan R, Feng X, et al. ATM activation is accompanied with earlier stages of prostate tumorigenesis..  Biochimica 
et biophysica acta. Oct 2006;1763(10):1090-1097.   Written authorisation obtained by Dr D. Tang on April 26th, 2014 
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did not detect any significant DDR signaling differences between normal and 
adenocarcinoma prostate tissues. 
Separately, and in support of a DDR cancer barrier in prostate cancer, investigators 
have established that a DDR-mediated tumor suppression activity restricts early-stage 
prostate cancer progression in mouse models 104; 105.  This senescence-mediated DDR 
barrier occurs at a stage associated with persistent DDR signalling and is analogous to 
human high-grade prostatic intraepithelial neoplasia (HG-PIN)106;107.  Further 
supporting this DDR-mediated cancer barrier, short telomeres (known to directly 
trigger the DDR) have been observed in human HG-PIN 108.  Together, these lines of 
evidence strongly suggest that the DDR-mediated cancer barrier during HG-PIN is at 
least partially driven by DDR signalling.  However, at the same time, the fact that DDR 
is persistently activated favours the outgrowth of malignant cells having defects in the 
DDR such as aberrations in the ATM cascade.  Cancer cells, including prostate cancer 
cells, acquire an intrinsic capacity to tolerate DNA damage during cancer progression.  
This can happen through the loss of redundant DDR signalling pathways such as the 
p53 pathway, allowing HG-PIN to move to invasive carcinoma in mouse models.  
DDR and DNA repair are essential for genome stability and prolonged cell survival, 
therefore, cancer cells must maintain other redundant DDR pathways functional.   
It is thus proposed that inactivation of these remaining DDR pathways could greatly 
sensitize cancer cells to DNA damage 109; 110.  The identification of these remaining 
pathways in prostate cancer could represent new therapeutic opportunities.  On their 
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own, these potential therapeutic avenues warrant a better characterization of active 
DDR pathways during prostate cancer progression104; 111.  
As described above, the DDR acts as a barrier against cancer progression.  Moreover in 
prostate cancer, it has also been shown that promyelocytic leukemia protein (PML) 
body formation is defective in prostate tumor cells but is active in benign prostatic 
hyperplasia (BPH)112.  PML was identified in the early 90’s as a gene target for 
translocations with the retinoic acid receptor gene in acute promyelocytic leukemia113.  
The expression of this protein in primary cells leads to cellular senescence.  PML acts 
as a tumor suppressor and is often lost in human cancers114.  It has been shown that 
PML represses genes involved in DNA replication, repair and checkpoints.  Indeed, 
PML represses E2F target genes and induces p53 and the DDR.  The decrease in the 
expression of genes required for DNA repair and checkpoints promptly after PML 
expression suggests a mechanism by which PML could contribute to the senescence 
cell cycle arrest, which we know involves DNA damage signals 115; 116; 117.  Vernier and 
colleagues investigated whether the PML/senescence pathway is important in human 
cancers, and to do so, they measured PML expression by immunohistochemistry in 
TMAs with samples from patients with benign or malignant prostate tumors112.  BPH is 
a benign prostate lesion characterized by the presence of senescence markers118  and 
low E2F target gene expression119.  In their study, PML staining in the normal prostate 
was very weak, but a few PML bodies could be distinguished.  In contrast, PML 
staining was stronger in BPH samples where many PML bodies were easily 
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distinguished.  Inversely, PML bodies were rarely distinguished in prostate cancer 
samples, including PIN, although they did detect some homogenous expression in the 
nucleus or cytoplasm.  Their results indicate that cells from BPH contain more PML 
bodies than cells from normal tissues or cells from the few cases of prostate 
carcinomas in their TMAs where PML bodies were visualized.  Taken together, they 
suggest that PML bodies may suppress malignant transformation in the prostate by 
promoting senescence, and that PML staining could be used to distinguish benign from 
malignant lesions. 
It is known that the retinoblastoma (Rb) pathway controls the cell cycle at the 
transcriptional level via repression of E2F target genes120; 121; 122.  Many E2F target 
genes mediate DNA repair and checkpoints, and, in their absence, cells          
accumulate DNA damage signals that are essential for activation of p53 and the 
senescence process115;116; 117.  According to this same group, the lack of PML bodies in 
tumor cells can explain why prostate tumors exhibit high levels of expression of E2F 
target genes such as EZH2123 and BRCA1124; 125 which is also one of the genes most 
efficiently downregulated in PML–senescent fibroblasts.   
Furthermore, DDR determines how normal and cancer cells react to cancer therapy 
such as DNA damaging RT or chemotherapies.  Indeed, DDR activity has been 
detected in prostate cancer tumors following chemotherapy 126.   
The identification of biomarkers that predict the kind of DDR responses particular 
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cells/tumors would mount against therapy could highly improve treatment selection 
and successes. Currently, the exact regulation and outcomes of DDR signalling in 
cancer cells, particularly in prostate cancer, remain relatively unknown. 
 
3.0 Biomarkers 
3.1 Prognostic vs. Predictive markers 
Prognostic markers may help clinicians guide their patients in their decision-making 
and avoid treatment and toxicities for men with slow growing cancer while promoting 
the initiation of treatment in the others.  Although ‘’predictive’’ and ‘’prognostic’’ 
markers are often used interchangeably, they are different127.  Prognosis refers to the 
ability to distinguish clinically important variation and reliably project the course, the 
progression, the pattern and the end of disease.  Prognostic markers are associated with 
prognosis, unrelated to the treatment received.  They predict the ‘’natural’’ outcome of 
the disease before a treatment is given or regardless of it.  As such, the treatment can 
change the prognosis in addition to the end point (local control, PSA control, overall 
survival or preservation of the prostate).  As for ‘’predictive’’ factors, they are those 
that foretell the response to a treatment.  In summary, predictive markers suggest the 
outcome of a treatment, thus allowing the identification of patients who will benefit 
from particular therapies, whereas a prognostic factor is a marker for gravity of a 
disease and outcome that is independent of treatment.  
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3.2 DDR as a tissue marker 
To our knowledge, the protein expression of DDR factors in tissues has not been 
studied as biomarkers for cancer biology.  Few studies have looked at tissue markers 
predictive of radiosensitivity in prostate cancer because the analyses are done on very 
small specimens obtained during prostate biopsies.  Moreover, there are no studies on 
post radiation prostatectomy specimens.  The Radiation Therapy Oncology Group 
(RTOG) has identified several biomarkers, from patients treated by RT under phase 3 
randomized trials.  Those markers are mainly involved in the cell cycle or apoptosis. 
The first biomarker studied by the RTOG was p53.  They found a statistically 
significant correlation between abnormal p53 protein expression and an increased risk 
of distant metastases (p=0.04), a decreased probability of progression-free survival 
(p=0.03), and a reduction in overall survival (p=0.02). Furthermore, patients with 
tumors exhibiting abnormal p53 expression who received RT with androgen 
deprivation therapy (ADT) who had tumors that exhibited abnormal p53 expression 
developed metastases faster (p=0.001) but this was not observed in patients treated by 
RT alone without ADT128.  The RTOG also evaluated patients in a different 
randomized phase 3 study.  Of the 777 patient cohort, 22% had abnormal p53 
expression defined as ≥20% cells with positive nuclear staining by 
immunohistochemistry (IHC) and this was associated with a decreased survival 
(p=0.014) and an increased risk of distant metastasis (p=0.013).  For patients treated 
with ADT, there was a correlation between the p53 status and cause-specific survival 
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(p=0.004).  When these patients were divided into subgroups based on p53 status, only 
the subgroup of patients with abnormal p53 was found to have a significant association 
between the assigned treatment and cause-specific survival (p<0.01).  Unfortunately, 
because all patients had received ADT, the question of a possible unfavourable 
interaction between abnormal p53 expression and the use of ADT compared with RT 
alone could not be resolved129.  Other markers that have been studied include DNA 
ploidy130, loss of p16 expression131; 132, Ki-67133; 134, mouse double-minute p53 binding 
protein homolog (MDM2) expression (an oncoprotein that promotes p53 
degradation)135, B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated x protein (Bax) 
expression levels136; 137, a quantitative assessment of cytosine, adenine, and guanine 
(CAG) base pair repeats on the androgen receptor gene138, Cyclooxygenase-2 (Cox-2) 
expression139, Signal transducer and activator of transcription 3 (Stat-3) expression140, 
Polymorphisms in the androgen receptor cytochrome P450 3A4 (CYP3A4)141 and 
protein kinase A RI-alpha (PKA) expression142.  Despite these numerous studies, an 
adequate biomarker is still not available for routine use within the clinic.  
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4.0 The Tissue Microarrays (TMAs) 
Tissue microarrays (TMAs) consists of paraffin blocks in which up to 1000 separate 
tissue cores are assembled in array fashion to allow multiple analysis such as 
immunofluorescence (IF), immunohistochemistry and in situ fluorescence hybrid- 
ization (FISH).  Kononen and colleagues, in the laboratory of Ollie Kallioniemi, 
developped this technique in 1998143.  Since tissue have been preserved in formalin and 
embedded in paraffin for sectioning before microscopic examination as a standard of 
care for over a century, this group defined a method for examining several histologic 
sections at one time by arraying them in a paraffin block. TMAs are produced by a 
method of relocating tissue from conventional histologic paraffin blocks such that 
tissue from multiple patients or blocks can be seen on the same slide.  To do this, a 
hollow needle is used to remove tissue cores as small as 0.6 mm in diameter from 
regions of interest in pre-existing paraffin-embedded tissues such as biopsies taken 
from patients or tumor samples following patients’ surgery.  These tissue cores are then 
inserted in a recipient paraffin block in a precisely spaced, array pattern.  Sections from 
this block are cut using a microtome and mounted on a microscope slide.  The number 
of spots on a single slide is variable depending on the array design.  Currently, up to 
600 cores can fit on a standard glass slide.  In this way, tissue from hundreds of 
archived pathologic specimens (one specimen per patient) can be represented on a 
single paraffin block that can be analyzed by any method of standard histological 
analysis, using a variety of techniques.  Figure 5 illustrates the creation of a TMA144.  
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The two major advantages of this technique are the fact that an entire cohort of patients 
can be studied by analyzing just a few slides and that all specimens are processed at 
once using identical conditions.  Nevertheless, a disadvantage of this technique is that 
it reduces the amount of tumor analyzed since each core represents a minuscule portion 
of the tumor.  In order to address this, a validation study determined how many tissue 
cores are required to adequately represent the expression of a particular antigen by a 
tumor145.   
It was determined that the analysis of two cores is comparable to analysis of a whole 
tissue section in more than 95% of cases.  To ensure adequate representation of the 
whole-section staining pattern, at least two, and in most cases three, punches are 
available for evaluation. One must also consider a few important aspects such as the 
technical expertise of the individual constructing the array blocks and slides as well as 
the fact that each tumor block is punched three times in various regions of the tumor 
mass, including both the leading edge and the tumor center.  It is also important to 
carefully outline areas of invasive carcinoma distinct from the non-invasive or in      
situ component and this process is performed by a technician and verified by a 
pathologist145.  
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This technique permits dramatic advancement of research based on the use of materials 
from biobanks.  Many institutions have developed TMAs that can then be shared for 
research.  For example, through a collaborative effort of the specialized programs of 
research excellence (SPORE) in skin cancer, a group146 has developed a melanocytic 
Figure 5: TMA                                          
A | Cylindric tissue cores (usually 0.6 mm 
in diameter) are removed from a 
conventional (‘donor’) paraffin block using 
a tissue microarrayer; these are released 
into premade holes of an empty 
(‘recipient’) paraffin block. Regular 
microtomes can be used to cut tissue 
microarray sections. The use of an 
adhesive-coated slide system 
(Instrumedics) facilitates the transfer of 
tissue microarray (TMA) sections on the 
slide and minimizes tissue loss, thereby 
increasing the number of sections that can 
be taken from each TMA block. B | 
Overview of a haematoxylin-eosin (H&E) 
stained TMA section. Each tissue spot 
measures 0.6 mm in diameter. C–E | 
Magnifications of sectors from tissue spots 
from different experiments. C | H&E 
staining of breast cancer tissue. D | 
Immunohistochemistry of breast cancer 
tissue using the HercepTest (DAKO). 
Brown membranous staining indicates 
strong ERBB2 expression. E | FISH 
analysis of the same case showing ERBB2 
gene amplification (red signals) but normal 
copy numbers of centromere 17 (green 
signals) 
Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nature 
reviews. Drug discovery. Dec 2003;2(12):962-972.                                     
Written authorization obtained by Dr Sauter on April 24th, 2014 
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tumor progression TMA to serve as a template for the examination of candidate 
biomarkers generated at a meeting in Gaithersburg147.  Similarly, OriGene 
Technologies is a corporation founded as a research tool company.  They provide 
TMAs that are created from high-quality tissue samples from the OriGene Tissue 
Biorepository, a growing collection of over >140,000 tissue samples, molecular 
derivatives, and associated clinical data that represent hundreds of pathology diagnoses. 
Our academic institution developed the TMA used herein (TMA-TFRI-Terry Fox 
Research Institute) starting in 2009 and by 2011, the TMA of the cohort of 300 patients 
was completed.  This TMA has allowed many researchers from our institution to make 
great advancements in cancer research resulting with the first publication in 2012148.  
Our laboratory has developed great interest and expertise in the development of TMAs 
whether in prostate or ovarian cancer.  Our team of assistants regularly updates the 
clinical data of the patients represented in the TMAs.  Furthermore, this technology has 
greatly encouraged the bench to bedside research where clinicians and basic 
researchers have come together to collaborate on research projects149.  
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Hypothesis and objectives   
 
1. Premiss: 
The DDR acts as a barrier against the progression of cancer beyond its early stages.   
This was shown in several pre-neoplastic human lesions, including prostate cancer. 
Activation of DDR signalling is detected during human prostate cancer progression 104; 
105, or following chemotherapy 150 and warrants the investigation of the DDR pathways 
involved.  Moreover, clinical correlations between DDR signalling and individual 
patients’ clinical outcomes have never been done.  This could allow us to identify 
novel biomarkers that can predict treatment outcomes and that can be used to develop 
better treatment strategies.  We have characterized DDR protein expression in prostate 
cancer, which is particularly promising with respect to potential treatment 
improvement based on DDR manipulation since DNA damaging agents such as RT are 
part of the first line of treatment.   
 
2. Hypothesis and objectives 
DDR activity is detected increasingly during cancer progression with a peak at the pre-
neoplastic state (HG-PIN) illustrating the DDR-mediated barrier to cancer 
progression.   Much less is known about the state of the DDR once the cancer 
progresses beyond pre-neoplasia to adenocarcinoma.  Will DDR remain stable, 
increase or decrease (Figure 6)?.  One hypothesis is that an increase in DDR may 
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indicate a defect in DNA repair and, hence, the relative radiosensitivity of those cells.  
Notably, DNA damaging agents are also used in cancer therapy and drugs targeting 
DNA damage response enzymes are exhibiting an exciting potential as new anti-cancer 
agents.  Our hypothesis is that the levels of DDR protein expression in prostate tissue 
will vary with the grade and behaviour of the prostate cancer.  Moreover, we expect 
that the levels of DDR protein expression are related to treatment response for 
individual patients.   
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Figure 6: Hypothesis 
Activation of DDR signalling has been shown in PIN.  Less is known about the state of the DDR once the 
cancer progresses beyond pre-neoplasia, from HG-PIN to adenocarcinoma.  Clinical correlations between 
DDR signalling and individual patients’ clinical outcomes have never been done, but we predict that they 
may provide clues to treatment response, especially where therapy targets DNA integrity.	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Our objectives are to: 
1) Use human prostate cancer tissue TMAs to characterize the occurrence of 
DDR expression. 
2) Correlate the activation of specific DDR markers with patient survival and 
responsiveness to treatment (biochemical recurrence free survival as measured 
by PSA and bone metastasis free survival). 
3) Determine the difference between DDR expression in epithelial cells and 
stromal cells using a specific epithelial mask to differentiate epithelial and 
stromal compartments when analyzing DDR activation signals. This 
epithelial-stromal specific DDR data will also be correlated to prostate cancer 
stages and clinical histories as in objectives 1 and 2 above. 
 
Our long-term goal is to identify new prognostic markers based on DDR activity in 
prostate cancer tissues that would allow better characterization of patients (i.e. low risk, 
high risk).  Eventually, we hope to find a predictive marker to determine which patients 
should be counselled towards surgery or RT.  
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CHAPITRE 2: EXPERIMENTAL RESULTS 
 
Novel streamlined DNA damage response signalling quantification in 
human prostate cancer tissue samples reveals a prognostic role for 
53BP1  
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ABSTRACT 
Background:  DNA lesions trigger a DNA damage response (DDR) that acts as a 
cancer barrier in several pre-neoplastic human lesions, including prostate cancer.  DDR 
signalling is based on a cascade of phosphorylation events that regulate DNA repair, 
cell cycle checkpoints and extracellular communications.  As such, the DDR also 
heavily influences the outcome of DNA damage based cancer treatments.  Here, we 
quantified the levels of selected DDR components and DDR activity proxy in archived 
human prostate cancer tissues and correlated their levels with patient clinical outcomes.  
Methods:  We used tissue microarrays (TMAs) built from archived human radical 
prostatectomy specimens of 300 men with prostate cancer and estimated the levels of 
DDR protein expression or activity in the nuclear stromal and epithelial compartments 
of normal and cancer tissues.  The protein expression of the DDR markers 53BP1, 
phosphorylated-H2AX, RELA and phosphorylated-CHK2 was quantified using 
immunofluorescence (IF) coupled to high-content automated imaging.  The 
quantification of our DDR markers was first validated on a small scale TMA of normal 
and irradiated (to induce DDR signalling) cultured human fibroblasts before final 
analysis on patient TMAs.  The validated markers were then used to quantify DDR 
signals on prostate cancer patients TMAs.  The data were quantified using binary 
layers commonly used to classify pixels in an image so areas can be analysed 
independently allowing detection of many morphological regions such as nuclei, 
epithelium and stroma.  Arithmetic operations were then performed to render values 
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corresponding to DDR activation.  Finally, the results were correlated with clinical 
outcome such as biochemical recurrence (BCR) and occurrence of bone metastasis.   
Results:  We found that low levels of RELA protein expression in the nuclear epithelial 
compartments of normal prostate tissue were associated with a reduced probability of 
biochemical failure.  Moreover, we also observed that low levels of 53BP1 protein 
expression in the nuclear epithelial compartments of normal and cancerous prostate 
tissue were associated with a lower incidence of bone metastasis (p=0.005).   
Conclusion:  This study confirms previous findings of p65 detectability in prostate 
cancer tissue and its usefulness as a prognostic factor.  All together, our study points 
out the presence of the DDR marker 53BP1 in prostate cancer tissues and its uses as 
prognostic value in patients with prostate adenocarcinoma.  
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1.0 Introduction 
Prostate cancer is the most frequently diagnosed cancer in Canadian men and is the 
third deadliest cancer in males after lung and colon cancers 1.  Some patients do not 
receive treatment while others will have prostatectomy, external beam radiation, 
brachytherapy, androgen deprivation therapy (ADT) or a combination of these 
therapies.  Currently, the decision to treat (e.g. surgery or radiation) or not (e.g. active 
surveillance) is based on the clinical and histologic features of the prostate cancer 2.  
To better stratify prostate cancer patients by prognosis, the identification of specific 
molecular biomarkers able to predict outcome would represent an important 
advancement over existing clinical tools.  Several research points out the importance of 
DDR responses in prostate cancer prognosis. DDR activity is detected in prostate 
cancer tumors following chemotherapy 3 and during prostate cancer progression with a 
peak at the pre-neoplastic state illustrating the DDR-mediated barrier to cancer 
progression 4.  Specifically, increased intensities of p-ATM, p-CHK2 and p-H2AX 
were observed in prostatic intra-epithelial neoplasia (PINs) compared to normal 
prostatic glands and carcinomas.  However, much less is known about the state of the 
DDR once the cancer progresses beyond PIN to adenocarcinoma, in addition the 
regulation and outcome of DDR signalling in cancer cells remains poorly understood. 
To preserve genomic integrity, and allow homeostasis state, cells require constant 
protection against the most lethal type of DNA damage; DNA double strand breaks 
(DSBs).  DSBs results from exogenous stresses, such as ionizing radiation, ultraviolet 
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light and chemical compounds (i.e. chemotherapy), as well as endogenous insults such 
as reactive oxygen species (ROS) production and DNA replication errors 5.    
To counteract DNA damage, cells have developed a mechanism that sense DSBs and 
initiate the DNA damage response (DDR).  The DDR is a signal transduction 
implicated in the inhibition of cell proliferation and therefore act to prevent cancer 
progression.  DDR act as a sensor to detect DSBs and initiate the activation of 
phosphoinositide-3 kinase-like kinase (PIKK) family.  PIKK is a apical transducers 
kinases including ATM (Ataxia Telangiectasia Mutated) which initiate a complex 
cascade orchestrated around phosphorylation events.  Signal mediators activated via 
phosphorylation by ATM/PIKK can amplify and expand the DNA damage signal from 
the source (DSBs) to downstream cellular mediators such as Chk2 and p53 DDR 
effectors leading to DNA repair, cell cycle arrest, apoptosis, senescence and even 
activating Nuclear Factor (NF)-κB inflammatory extracellular signals 6; 7.  ATM 
induces the activation of the nucleosomal histone variant H2AX, which in turn 
enhances the local recruitment of DDR factors on the chromatin including the tudor-
domain p53 binding protein-1 (53BP1).  Phosphorylated H2AX (p-H2AX) and 53BP1 
rapidly co-localize to DSBs forming characteristic structures termed DNA damage foci.  
ATM also phosphorylates the kinase CHK2 (checkpoint kinase-2), which promotes 
growth arrest and p53, a tumor suppressor and transcriptional regulator that coordinates 
repair and cell cycle arrest 8.   
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The DDR acts as a barrier against the progression of cancer beyond its early stages.  
Indeed, the DDR cascade leads to transient cell cycle arrest and DNA repair, cell death, 
or permanent cell cycle arrest (cellular senescence) preventing the accumulation of 
cells containing mutations and cancer development 9; 10.  Previous research using 
animal models shows that the activation of numerous oncogenes or the loss of tumor 
suppressors result in DNA replication stress and DNA damage that triggers the DDR 
leading to cellular senescence or death of oncogene-transformed cells preventing tumor 
formation.  Similarly, a DDR-mediated tumor suppression barrier restricts early-stage 
prostate cancer progression in mouse models 11; 12.  This senescence barrier occurs 
simultaneously with the detection of persistent DDR signalling and at a cancer 
progression stage analogous to human high-grade prostatic intraepithelial neoplasia 
(HG-PIN) 13; 14.  Further supporting this DDR-mediated cancer barrier, short telomeres 
(known to directly trigger the DDR) have been observed in human HG-PIN 15.  All 
together, these observations strongly support that the DDR-mediated cancer barrier 
restricting progression during HG-PIN is at least partially driven by DDR signalling.  
However, the fact that DDR is persistently activated could promote the outgrowth of 
malignant cells bearing a defect in the DDR as an aberration in the ATM cascade.  
Cancer cells, including prostate cancer cells, are known to acquire an intrinsic capacity 
to tolerate DNA damage during cancer progression.  In mouse carcinoma cells, this can 
happen through the loss of redundant DDR signalling pathways such as the p53 
pathway, allowing HG-PIN to progress to invasive carcinoma cells 11; 12.  However, in 
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general, the DDR and DNA repair functions are absolutely essential for cell survival; 
thus cancer cells must maintain other redundant DDR pathways functional.  It is 
therefore proposed that inactivation of these remaining DDR pathways could greatly 
sensitize cancer cells to DNA damage 16; 17.   The identification of these remaining 
pathways in prostate cancer could represent a new therapeutic opportunities in 
combination with current RT.  On their own, these potential therapeutic avenues 
warrant a better characterization of active DDR pathways during prostate cancer 
progression 4; 18. 
In the present study, we investigated the effect of DDR signalling in DNA repair 
because our group has already addressed the prognostic value of the p65 subunit of 
(NF)-κB in prostate cancer (p65) where it was observed that a high level of nuclear p65 
in tumors is associated with more aggressive prostate cancer 19.  In addition, we 
examined the possibility that DDR activity could be correlated with patients’ clinical 
outcomes.
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2.0 Materials and Methods 
 
2.1 Tissue Microarrays (TMAs) Construction 
 
The tissue microarrays (TMAs) used in this study were paraffin blocks in which up to 
300 separate paraffin-embedded tissue cores were arrayed.  Briefly, a hollow needle is 
used to remove tissue cores as small as 0.6 mm in diameter from regions of interest in a 
paraffin-embedded tissue block made from patient’s biopsies, tumor samples or 
cultured cells.  The samples were then embedded in a recipient paraffin block in a 
precisely spaced, arrayed pattern.  Sections were made using a microtome, mounted on 
a microscope slide, and processed/analyzed by any method of standard histological 
analysis19; 20; 21.  
 
2.2 DDR markers validation study: TMA-cell and TMA-tissue  
We established a specific procedure to measure DDR activity in formalin fixed paraffin 
embedded (FFPE) samples (TMA-cell).  Briefly, the TMA-cell consisted of BJ-u cells 
(normal fibroblasts) exposed to a 10 Gy dose and different times of recovery following 
irradiation (30 minutes, 2h, 8h, and 24h) to induce DDR signalling.  The negative 
control consisted of non-irradiated BJ-u cells.  Figure S1 illustrates the construction 
and map of the TMA-cell.  The selected DDR antibodies were optimized using the 
TMA-cell and validated on TMA-tissue consisting of tissue cores from patients having 
had transurethral resection of the prostate (TURP), prostatectomy or ovariectomy.  
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Once all antibodies were validated on the first two TMAs, they were then used on our 
cohort of patients, TMA-TFRI (Terry Fox Research Institute).  
 
2.3 TMA- Terry Fox Research Institute (TFRI) / Cohort of patients  
The TMA-TFRI consists of 300 patients treated by surgery for their prostate cancer.  
From the FFPE tissue samples, tumor areas were selected based on the 
hematoxylin/eosin (H/E) - stained slides analysed by a pathologist.  FFPE tumor blocks 
were then cored using a 0.6 mm diameter tissue arrayer and resultant cores were 
arrayed into a grid in a recipient paraffin block.  All patients were distributed on three 
TMAs, a total of 100 patients per TMA.  Each TMA consisted of one core of tumor 
sample and one core of normal prostatic glandular tissue per patient (one set per 
patient).  Every TMA was also duplicated so that two different sets per patient was 
represented on two different TMA slides.  These TMAs were then sectioned, stained by 
H/E and immunohistochemistry (IHC) of high molecular cytokeratin (HMCK) and 
underwent an independent pathology review to confirm the histology of each core. 
The current study was based on a cohort of 300 prostate cancer patients whose 
paraffin-embedded primary prostate cancer specimens were used to construct TMA-
TFRI.  All patients had radical prostatectomy between 1992-2006.  All patients with 
the exception of 12 (these cases were excluded) had no prior treatment.  The median 
patient follow-up was 100.5 months.  Biochemical recurrence (BCR) was defined as a 
prostate specific antigen (PSA) above 0.3ng.ml−1 after date of surgery (RP).  
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Recurrence-free interval was defined as the time between RP and the date of first PSA 
increase above 0.3ng/mL.  The final staging, grading and histological diagnosis was 
based on the clinical pathology report from the patients’ file.  The main clinical 
parameters of the cohort are listed in Table 1.   All patients provided informed consent 
and the institutional review board approved this retrospective analysis. 
 
2.4 Immunofluorescence technique (IF) 
We optimized the immunofluorescence (IF) protocol to detect total nuclear signal of 
specific proteins that are part of DDR pathway.  
To ensure coverage of all prostate cancer cells, even in their most undifferentiated state, 
a combination of cytokeratin 18 (CK18), cytokeratin 19 (CK19) and PSA was used 
(epithelial mask).  They were all labeled to emit in the orange channel, tetramethyl 
rhodamine isothiocyanate (TRIT-C).  Slides were also stained with 4',6-diamidino-2-
phenylindole (DAPI - blue) to identify nuclei (nuclear mask).  Selected DDR 
antibodies were labeled with Cy-5 (red cyanine dyes) or with FITC (green fluorescein 
isothiocyanate).  This allowed us to define epithelial-stromal specific staining of the 
DDR antibodies, and to define whether this staining was nuclear or cytoplasmic. 
The IF protocol consisted of a two steps procedure.  The first part using an 
autostainer and the second part directly on the bench.  The slides were first 
deparaffinized and then washed in toluene.  The 4µm tissue sections from 
TMAs were then stained with the Benchmark XT autostainer (Ventana Medical 
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System Inc.).  Antigen retrieval was obtained using Cell Conditioning 1 
(Ventana Medical System Inc., #760-501) for 60 minutes.  Pre-diluted primary 
antibodies (anti 53BP1 (rabbit, Clone 304, lot #A3 1:1000), anti-p-H2AX 
(mouse, JBW 301,1:2000), RELA / NfKB-p65 (mouse, F-6, Santa Cruz 1:25), 
pCHK2 (rabbit, Thr68, Lot 11, #2661, 1:500)) were manually added to the 
slides and incubated at 37˚C for 60 minutes.  All following steps were manually 
done at room temperature under conditions to protect slides from light.  The 
specimens were then blocked with a protein-blocking serum-free reagent (Dako) 
at room temperature for 20 minutes followed by a 60 minutes simultaneous 
incubation in the dark with secondary antibodies: anti-mouse Cy-5 (#A10524, 
Life Technologies Inc., ON, CANADA) for mouse primary antibodies and anti-
rabbit Alexa Fluor488 (A488) (#A11008, Life Technologies Inc., ON, 
CANADA) to detect rabbit primary antibodies, both diluted at 1:250 in 1X PBS.  
Between incubations, specimens were washed in PBS for 10 min.  Because 
epithelial mask-specific mouse antibodies are used in addition to the DDR-
specific antibodies above, TMAs slides were blocked 60 minutes with Mouse-
On-Mouse blocking reagent (MKB-2213, Vector Laboratories, CA, USA) (1 
drop in 250 µL PBS) and then incubated for 90 min at RT with anti-PSA (1:100 
in PBS).  After two successive washes, TMAs slides were incubated for 45 
minutes at RT with secondary fluorescent anti-goat Cy3 (#705-165-003, 
Jackson ImmunoResearch Laboratories Inc., PA, USA) diluted at 1:250 in PBS.  
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After two more successive rinses, TMAs slides were blocked once again with 
Mouse-On-Mouse blocking reagent overnight at 4°C.  Subsequently, they were 
incubated for 90 minutes at RT with a mix of anti-CK18 and anti-CK19, both at 
1:100 in PBS.  After two rinses, TMAs slides were incubated 45 minutes at RT 
with secondary fluorescent antibody anti-mouse Alexa Fluor546 (A546) 
(#A10036, Life Technologies Inc., ON, CANADA).  TMAs slides were then 
rinsed three times and incubated 15 minutes at RT with a 0.1% (w/v) solution of 
Sudan Black in 70% ethanol, to quench tissue auto-fluorescence.  Finally, 
TMAs slides were mounted with anti-fade mounting medium containing DAPI 
for nuclei staining.  Slides were stored at 4°C and scanned the next day.  A 
negative TMA slide was used in parallel where PBS replaced all the primary 
antibodies. 
 
2.5 Image Analysis 
The immunofluorescence results were analysed and quantified using the 
ViosiomorphDP software (Visiopharm, Denmark) following whole slide mosaic digital 
images acquisition using the Olympus software linked to our automated microscope.  
The 4 different colour channels were DAPI, FITC, TRIT-C and Cy-5 each associated 
to a particular mask.  DAPI stains nucleus, TRIT-C the epithelium whereas FITC and 
Cy-5 were associated to the DDR antibodies of interest. The means fluorescent 
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intensities (MFI) were evaluated based on dye used.  Hence, the image content is 
« Segmented ».  Binary Layers are commonly used to classify pixels in an image so 
areas can be analysed independently.  The use of many binary layers allowed the 
detection of the morphological regions.   Arithmetic operations (AND, NAND, OR, 
NOR, etc.) were performed on those binary layers allowing even more segmentation 
and measurements options.  This allows a quality control in order to reject cores from 
our analysis showing less than a certain percentage of epithelia or simply to reject 
damaged cores.    
MFI was calculated based on the sum of the intensities of each pixel (every nucleus 
being divided in many pixels) divided by the number of pixels in the nucleus, assuming 
that MFI is proportional to the number of nucleus. 
 
2.6 Statistic analysis 
Statistical program SPSS was used for all data analysis (SPSS 16.0 statistical software 
package, SPSS Inc, Chicago, IL, USA).  The correlation with clinico-pathological 
variables was estimated with a Pearson correlation coefficient test.  BCR-free survival 
and bone metastasis free curves were plotted using the Kaplan–Meier estimation and 
the log-rank test was used to evaluate significant differences.  Comparison between 
non-malignant cores and matched tumor cores were assessed using a paired t-test.  
Univariate and multivariate proportional hazard models (Cox regression) were used to 
estimate the hazard ratios for each DDR marker variable.   Multivariate analysis was 
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performed using a forward stepwise hazard model on univariate analysis required for 
entry into the model.  Additional clinico-pathological variables included pre-operatory 
PSA, Gleason score (GS), surgical margin status, extra-capsular extension (ECE) and 
seminal vesicles involvement (SVI).  A p-value < 0.05 was considered to be 
statistically significant. 
 
3.0  Results 
 
3.1 DDR markers validation on TMAs  
 
In order to evaluate DDR signaling in patients’ prostate cancer tissue samples, we first 
established a specific and quantifiable methodology to measure and quantify DDR 
activity in paraffin-embedded samples.  We created a TMA-cell (Figure S1 A-B) 
consisting of cultured non-irradiated control human fibroblasts and similar cells 
irradiated with 10 Gy X-Ray and fixed at selected time intervals to allow DDR 
progression through its multiple signalling stages.  
Following the immunofluorescence staining on the TMA-cell, we were able to detect a 
specific appearance of H2AX phosphorylation (p-H2AX) in irradiated cells correlated 
to the expected rapid increase in H2AX phosphorylation followed by an apparent 
decrease in signal intensity over time consistent with the occurrence of DSBs repair 
(Figure 1).  When analyzing images at higher resolution, we observed the appearance 
of typical p-H2AX DNA damage foci, with residual foci persisting up to 24 hours after 
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irradiation despite the global decrease in p-H2AX (Figure 1).  Using the 
immunofluorescence technique, we were able to simultaneously detect more than one 
DDR marker in a single cell (different colors for each markers).  This was illustrated 
by the simultaneous detection of 53BP1 (red) and p-H2AX (green) showing that 
53BP1 rapidly colocalizes with p-H2AX at DNA damage foci following irradiation 
(Figure 1). 
We also detected the appearance of intense residual DNA damage foci at sites that 
were not repaired efficiently (persistent DDR foci associated with a senescence 
response 22).  This initial increase in signal is not observed using 53BP1, which is a 
DDR protein known to be already present in the nucleus before damage, but that 
relocalizes at sites of DNA damage as long as the repair is not fully completed 
(persistent DDR foci).   
Other selected DDR antibodies were similarly validated on TMA-cell (RELA, p-21 
and p-CHK2 (data not shown).  Finally, we applied a software-based nuclear mask 
using the DAPI staining as a reference to automatically isolate individual nuclei in a 
TMA-cell core (Figure S1-C).  Our results confirm that by choosing automated multi-
color immunofluorescence image acquisition pipeline, we were able to detect DDR 
signalling and automatically identify substructures like nuclei in FFPE samples.   
We then determined whether masking segmentation could also be applied to accurately 
separate epithelial and stromal tissues compartments in real tissue cores.  To answer 
this question, we applied paraffin-validated antibodies on real tissue TMAs as 
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described in materials and methods.  As shown in Figure 2A and 2B, we were able to 
validate our immunofluorescence technique, which provides a clear and a channel-
independent multicolor IF signals on tissue cores (representative prostate cancer TMA-
TFRI tissue core), a representative full slide prostate cancer TMA-TFRI mosaic scan is 
shown in figure S2.  Additionally, our epithelial and nuclear IF masks were accurately 
and reliably detected by our software-based image segmentation analysis (Figure 2-C).  
 
3.2 Nuclear DDR markers quantification in IF segmented images 
 
Following successful validation of DDR markers staining and image segmentation in 
TMAs, we were interested in specifically quantified nuclear DDR signalling, which 
normally would represent the major cellular compartment of activity for the selected 
potential DDR biomarkers (H2AX is a nuclear histone phosphorylated in situ, 53BP1 is 
a nuclear protein that relocalizes within the nucleus following DNA damage, CHK2 is 
phosphorylated in the nucleus, and RELA relocalizes from the cytoplasm to the 
nucleus upon activation).  Consistent with what we know about the DDR (Figure 3-A), 
our software-based quantification of nuclear DDR signal reveal that the 
phosphorylation of ATM targets such as p-H2AX and p-CHK2 was rapidly increased 
following DNA damage while 53BP1 levels remain relatively stable (as expected for a 
protein that is not stabilized/degraded following DNA damage but rather relocalizes to 
DNA damage foci).  Alternatively, the p53 transcriptional target p21 was gradually 
increased, as we were expecting for a protein that increases in quantity following 
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regulation at the RNA level.  Additionally, in Figure 3-B and S-3, we showed that the 
values acquired are based on the analysis of thousands of nuclei per data point.  These 
results confirm and validate our software-based DDR quantification analysis. 
 
3.3 DDR Activity quantification and correlations with clinico-pathological 
parameters 
 
We next performed IF and automated image acquisition/analysis on the 300 prostate 
cancer patients of the TMA-TFRI.  The final data acquired represented segmented MFI 
values of DDR markers p-H2AX, 53BP1, p65 and p-CHK2 for every patient’s core as 
described in section 2.4.  We performed a quality control of the data by a visual 
inspection.  As described in section 2.2, each patient had a duplicate of its normal and 
tumoral cores.  MFI of each set of duplicate were plotted as shown in figure 4-A.  
Cores that showed 2 fold differences in their MFI with its duplicate core from the same 
tissue section (for any DDR marker under analysis) was visually inspected by two 
independent collaborators in order to exclude from analysis the cores with an obvious 
explanation (ex: tear or spot in a core).  Few cores were rejected because of 
discrepancies in the results (Figure 4-B).  Although all R2 were statistically significant 
(p < 0.05), they had relatively low values (0.03-0.16).  These poor R2 values can be 
explained by the true biological variability even between cores coming from different 
nearby areas from the same tissues.  Indeed, even though duplicates were taken from 
the same patient, they are not taken from the exact same region of the tumoral or 
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normal tissue.  After the quality control, the remaining samples were used to assess the 
correlation between the DDR activity and patient clinical parameters.  To assess the 
predictive potential of each DDR activity antibody and variables, we performed 
Kaplan-Meier estimation based on biochemical recurrence (BCR: defined as a relapse 
of disease based on a PSA value >0.3ng/mL following surgery) and bone metastasis as 
shown in figure 5.  We used either the receiver operative characteristic (ROC) curves 
or the median calculation value of the MFI obtained by image analysis to determine the 
threshold value for each DDR marker.   
We observed a statistically significant association between 53BP1 protein expression 
and bone metastasis development.  Indeed, Figure 5 (E and F) shows that a weak 
53BP1 signal in the stroma or epithelium of tumors is associated with better prognosis 
in respect to bone metastasis development (p=0.005).  Furthermore, we found that a 
lower RELA in the nuclear epithelium of normal core was associated with higher 
biochemical recurrence free (p=0.002) (Figure 5C).  The MFI of p-CHK2 or p-H2AX 
in the epithelium or stromal did not significantly predict BCR or metastasis free 
survival.  Univariate and multivariate Cox regression analyses confirmed the 
association between the MFI of 53BP1 and bone metastasis free survival and included 
other clinico-pathological parameters such as gleason score (GS), extracapsular 
extension (ECE), seminal vesicle invasion (SVI) and status of surgical margins, which 
internally validated the analysis (Table 2).  As for RELA, we found an association, in a 
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multivariate model including the same clinico-pathological parameters, where RELA 
was retained as a variable able to predict BCR. 
Pearson correlations were also done between all validated DDR markers and clinico-
pathological parameters such as the age of diagnosis, PSA, GS, lymph node invasion 
(LNI), SVI, ECE, status of surgical margins, castrate resistant prostate cancer status 
(CRPC) and patholocical staging (pTNM) as shown in Table 3.  Once again, we 
observed a statistically significant correlation between 53BP1 signal and development 
of bone metastasis as well as with SVI, CRPC and pTNM.     
Using a paired T-test, we evaluated the differences in DDR markers expression within 
the adjacent normal and tumor cells.  Our results indicated significant differences for p-
CHK2, RELA, 53BP1 and p-H2AX expression within the epithelium compartment.  In 
the stroma, RELA and pH2AX showed significant differences between the adjacent 
normal and tumor cells (Table 4).  We also found that p-CHK2 showed increased 
intensity in the epithelium of the normal cores while RELA was more activated in both 
the epithelium and stroma of the normal cores.  Alternatively, 53BP1 showed a higher 
signal in the epithelium of the tumoral cores. As for p-H2AX, it was more activated in 
the normal cores (epithelium and stroma) when compared to the tumoral cores.  
Overall, except for 53BP1, our results reveal that DDR activity appears higher in 
normal tissues surrounding the prostate cancer tissue suggesting that detected DDR 
activity is generally reduced in advanced prostate cancer. 
 
	   60	  
4.0  Discussion 
Nuclear structures termed “DNA damage foci” are hallmarks of DDR activation 8; 22.  
For example, 53BP1 is a nuclear protein that relocalizes to DNA damage foci, while 
H2AX is a histone that becomes phosphorylated at sites of DNA damage (named p-
H2AX when phosphorylated).  To preserve genome integrity, cells need to protect 
themselves against DSBs, which are the most lethal type of DNA damage.  Once cells 
detect DNA breaks, the DDR is initiated which is essential to stop the proliferation of 
cells with genomic instability, and therefore, prevent cancer progression.  DDR will 
lead to temporary cell cycle arrest and DNA repair, apoptosis, or senescence 
preventing cells with accumulated mutations to replicate and progress into cancer.  
Importantly, this cellular response determines how normal and cancer cells react to 
DNA damaging agents used for cancer therapy (radiation therapy and chemotherapy).  
The DDR, a central tumor suppression mechanism in mammals acts as a barrier against 
cancer progression.  There is available data indicating that the DDR machinery is 
commonly activated in major types of human melanocytic nevi and precursor 
dysplastic and adenomatous lesions in the lung, breast, colon, urinary bladder and 
prostate 4; 23; 24; 25; 26; 27.  It has been suggested that abnormal cell cycle progression via 
over-expression of cyclin E, Cdc25A, and E2F1 produces “DNA replication stress” 
that leads to activation of the DNA damage response, including ATM activation and 
phosphorylation of its downstream targets, p53 Ser15 (p53pSer15), H2AX, and Chk2 
23; 24. 
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To refine our understanding of DDR signalling during cancer progression, we 
characterized this DDR activity in human prostate tissue and correlated it with clinical 
outcomes.  In the present study, we selected prostate cancer, as it was particularly 
promising since preliminary data described DDR activation during prostate cancer 
progression 4 with higher DDR seen in PIN as compared to normal prostate or 
adenocarcinomas.  However, little is known on DDR activity level from the PIN state 
to adenocarinoma.  Whether these levels of DDR activity will remain the same, 
increase or yet decrease is not much known.  We found that prostate cancer cells show 
a decreased level of DDR as compared to normal cells in our cohort of 300 prostate 
cancer patients.  As it has already been shown, ATM is activated in earlier stages of 
prostate tumorigenesis (PINs) leading to an increased level of DDR.  We believe that 
after genetic instability, adenocarcinoma develops.  The growth of tumor cells have 
survived the pressure of the immune system and prostatic cells have probably only 
stabilized their genome when becoming more aggressive, adenocarcinoma cells.  These 
findings could be used in a clinical setting by helping patients to make a decision 
regarding their treatment (ie: surgery or radiotherapy). 
In normal cells, an increasing level of DDR may indicate a defect in DNA repair and 
therefore an increased sensitivity to radiation.  Indeed, cells that fail to repair will have 
even more difficulty to repair themselves following the DNA damage.  One could also 
assume that a decrease in DDR activity would translate to more radio-resistance since 
cells would have accumulated more changes due to genetic instability and thus 
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accumulation of more mutations leading to more resistant to treatment.  As for cancer 
cells, if a defect in the damage recognition exists within the cell, those cancer cells will 
ignore the damage and consequently would be more radio-sensitive as they would be 
less able to repair themselves.   
One of the two distinct pathways that have evolved to eliminate DSBs is homologous 
recombination (HR), which requires the cells to be in the S or G2 phase of the cell 
cycle, when DNA replication generates the sister chromatid to direct the repair process.  
HR has a role to preserve the genome’s integrity as well as a role in faithfully 
duplicating the genome by providing critical support for DNA replication and telomere 
maintenance.  53BP1 plays a major role in HR: it is a central component of chromatin-
based DSB signalling.  Important structural elements in 53BP1 include the breast 
cancer 1 (BRCA1) carboxy-terminal (BRCT) repeats, the tandem Tudor domains and 
28 amino-terminal Ser/Thr-Gln (S/T-Q) sites, which are phosphorylated, at least in part, 
by ATM kinase 28.  Loss of 53BP1 or its failure to localize to damaged chromatin 
significantly reduces the phosphorylation of ATM targets such as p53, CHK2 and 
BRCA1 and, as a consequence, leads to G2–M checkpoint defects and genomic 
instability.  Upon entry into S phase, BRCA1 helps to switch the mode of DSB repair 
by excluding 53BP1–RIF1 complexes from the DSB, thus enabling extensive DSB 
resection and the initiation of HR 29.  It has been demonstrated that when 53BP1 is 
defective, formation of the mammary tumors that normally develop in BRCA1 mutant 
mice is suppressed 30.  Mouse BRCA1-associated mammary tumors have significant 
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similarities to human BRCA1-associated breast cancer in regard to tumor 
aggressiveness, high incidence, mutations, and genetic instability.  The same group has 
also found that inactivation of 53BP1 restored the DNA repair function that is lost 
when BRCA1 is mutated.  Using a strain of mice with a defective BRCA1 gene, the 
team observed that the mice frequently developed mammary tumors similar to human 
breast cancers, but tumor formation was largely suppressed when the mice also were 
lacking the functional protein 53BP1.  Furthermore, both BRCA1 and 53BP1 are 
capable of binding to replication-associated chromosome breaks; so when both proteins 
are present, BRCA1 displaces 53BP1, the HR machinery has full access to the breaks, 
and HR proceeds.  In BRCA1-deficient cells, the binding of 53BP1 to the site of DNA 
damage interferes with the DNA repair activity of HR proteins, so an alternative 
pathway that is more prone to produce mutations repairs the damage.  When 53BP1 is 
absent, BRCA1 is not needed to displace it so HR can take place normally.  Our 
findings showed that less 53BP1 is associated with a better prognosis.  We could 
eventually also evaluate the presence or absence of BRCA in our cohort of patients to 
further explain these findings.  Treatment options for localized prostate cancer in 2014 
are mainly radiation therapy or surgery.  Both have shown similar survival outcomes in 
low and intermediate risk prostate cancer patients.  Contemporary radiotherapy 
approaches such as intensity-modulated radiation therapy (IMRT) have permitted 
increased delivery of radiation to the prostate while sparing adjacent organs and 
reducing the potential for acute and chronic toxicity.  However, proctitis, cystitis, and 
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erectile dysfunction remain significant complications of high-dose radiotherapy.  In 
turn, local failure after radiotherapy remains 20%–35% in intermediate and high-risk 
patients, leading to increased metastasis and lower survival. Hormonal therapy has a 
proven value when combined with localized radiotherapy in intermediate and high risk 
prostate cancer patients, but carries its own set of morbidities, including increased 
cardiovascular and thromboembolic risk.  Novel agents with more attractive side effect 
profiles that can be combined with radiotherapy to improve local control in high-risk 
patients and/or permit a dose reduction in lower-risk patients would be of great value.  
A developing strategy to improve efficacy at lower ionizing radiation doses is the use 
of radiosensitizers to target recognition and repair of DNA damage 31.  Poly ADP 
ribose polymerase (PARPs) are a family of enzymes that are activated by DNA damage 
and participate in repair of single-strand breaks by activating XRCC1 and base-
excision repair, and DSB likely through influence on both the HR and NHEJ 
mechanisms.  After a DSB, PARP are rapidly recruited and trigger poly-ADP 
ribosylation of PARP itself, histones, and other mediator proteins to stimulate 
chromatin loosening and DNA repair.  It has been observed that PARP is activated by 
RT and chemotherapy agents, and this has provided the rationale to examine the 
combined effects of PARP inhibitors and genotoxic therapy in tumor models and in 
clinical trials 32; 33; 34.  A number of other mutations that decrease HR repair responses 
can also sensitize cells to PARP inhibitors, including defects in the inositide 
phosphatase PTEN, a gene commonly inactivated in prostate cancer 35.  Cells deficient 
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in DNA DSB repair have been shown to be sensitized by PARP inhibitors to DNA 
damaging agents36.  Because the DDR controls cellular responses that are absolutely 
essential for radiotherapy treatment outcomes, biochemical components of this 
signalling cascade become potential pharmaceutical targets for treatment optimization. 
Cancer cells, including prostate cancer cells, acquire an intrinsic capacity to tolerate 
DNA damage during cancer progression.  This can happen through the loss of 
redundant DDR signalling pathways such as the p53 pathway, allowing HG-PIN to 
evolve into invasive carcinoma in mouse models.  Because the DDR and DNA repair 
are absolutely essential for cell survival, cancer cells must maintain other redundant 
DDR pathways functional. It is thus proposed that inactivation of these remaining DDR 
pathways could greatly sensitize cancer cells to DNA damage 16; 17.  Alternatively, 
gaining information about the initial “DDR state” of the tumor could help in predicting 
whether a particular cancer will respond better to DNA damaging agents during 
treatment.  Finding new biomarkers predicting what kind of DDR individual 
cells/tumors mount against radiotherapy has the potential to improve treatment 
selection and successes.  Currently, the exact regulation and outcomes of DDR 
signalling in cancer cells remain relatively unknown.  Furthermore, because tumor cells 
that are BRCA1-deficient are driven to turn to other, less faithful DNA repair pathways 
and they may become resistant to chemotherapy/RT by acquiring additional mutations.  
Our cohort of 288 evaluated patients consisted mostly of low risk patients with only 29 
patients with Gleason > 7 and 79 patients with PSA > 10 ng/mL which could explain 
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the low number of bone metastases (19/288) and the average follow up of 101.5 
months might also explain this low number of events.  Although, we did find a 
statistical significant relation of 53BP1 and bone metastasis free survival as well as p65 
and BCR, we believe more results pertaining to biochemical control, bone metastases 
as well as prostate cancer survival will be obtained with longer follow-up of our cohort.   
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5.0  Conclusion 	  
DDR is a complex signalling network and its failure causes genomic instability, an 
underlying cause of cancer.  Today, the tumor’s biology in individual prostate cancer 
patient is still not taken into consideration for clinical management of the disease.  In 
an era of evolving personalized medicine, we confirmed that RELA (p65) and showed 
that DDR marker 53BP1 have prognostic value in patients with prostate 
adenocarcinoma.  Patients expressing reduced amounts of 53BP1 have a better bone 
metastasis free survival (p=0.005) and those with reduced amounts of RELA have a 
better biochemical control (p=0.002).  These findings were also correlated in univariate 
and multivariate cox regression analysis.  Even though our follow up is quite long 
(101.5 months), a longer follow-up is probably needed to translate into a correlation 
with survival since prostate cancer patients have very good prognosis and develop 
metastasis leading to death many years after the initial curative treatment.  Future work 
should focus on designing the ways to better predict responses of individual patients to 
DNA damaging therapies including radiation and various chemotherapeutics that are 
used in first line of treatment.  These predictions could be based on the genetic and 
functional profiling of patient specific tumors.  This may facilitate selection of a proper 
modality or combination of treatment options on an individualized basis and also 
optimize the dosage of such therapies according to the state of the DNA damage 
checkpoint and repair machineries of each individual patient.  	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Figure Legends 
 
Figure 1: Detection of DDR activity and DDR foci in paraffin embedded cells 
using multicolor immunofluorescence  
Normal human fibroblasts were left untreated or irradiated with 10 Gy X-Ray and left 
to recover for the indicated time periods.   Cells were then fixed and embedded in 
paraffin to mimic tissue sections.  Cores were extracted from the paraffin blocks and 
arrayed on a control TMA tissue micro array (TMA-cell).  The TMA-cell was 
processed for immunofluorescence and stained.   The TMA was stained for p-H2AX 
(green) and 53BP1 (red) and the nuclei counterstained with DAPI (blue).   
Top panel: color merge; Middle panels: grayscale representation of extracted p-H2AX 
or 53BP1 signals (originally green and red, respectively).  The bottom panel shows 
magnified color merge (zoomed) inset boxes that are apparent in the corresponding top 
panels.     
Notice that the DNA damage foci detected in paraffin-embedded irradiated cells 
appears in yellow (arrow pointing at yellow DNA damage foci) because p-H2AX 
(green) and 53BP1 (red) are co-localized at damage sites in the cell).  Not all foci are 
highlighted.  53BP1 co-localization with p-H2AX is a definitive biomarker of DSB-
initiated DDR signalling. 
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Figure 2:  Multicolor immunofluorescence and mask segmentation analysis in 
prostate cancer TMA core 
A- Immunofluorescence image of one selected  TMA core from prostate cancer tissue 
at 20-X magnification.  This image is a 4-color merge, superposing the following: 
Epithelial mask (Ep; orange - A546 (CK18 and CK19) and Cy3 (PSA)), 53BP1 
(red; CY5), p-H2AX (green; FIT-C) and nuclein (blue; DAPI) 
B- Extraction of individual color channels from image above in color and gray scale to 
enhance contrast. 
C- False color image generated following the analysis of the core in a-b using the 
VisioMorph and TissueMorph software.  The software is used to detect and define 
the position of masks based on selected immunofluorescence signals.  The total 
core is detected (purple) and superposed with the epithelial mask (light blue) and 
the nuclear mask (pink in the epithelial mask and cyan in the stromal area).  in 
individual TMA cores.  
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Figure 3: Software-based quantification of immunofluorescence-detected DDR 
activity in paraffin embedded cells  
Total cores from control and irradiated (10 Gy X-ray) paraffin-embedded fibroblast in 
TMA-cell were analyzed using automated detection of immunofluorescence signal 
intensity in the cell nucleus (DAPI nuclear mask).  Quantifications were performed for 
p-H2AX, 53BP1, p21 and p-CHK2.   
A- Quantified expression data for the different DDR markers is illustrated as the 
percentage of mean fluorescence intensity (MFI) relative to the non-irradiated 
control at 0 hours (Y-axis).  The X-axis represents the time in hours after irradiation 
with 10 Gy X-Ray.  
B- Immunofluorescence images used for the quantification above.  The images are     
generated by the extraction of the individual color channels and conversion to gray 
scale to enhance contrast.  N = Number of nucleus analyzed in the quantified signal. 
 
Figure 4: Quality Control of DDR data on duplicate samples for prostate cancer 
TMA 
A- The mean fluorescence intensity (MFI) of 53BP1 in total nuclear-epithelial sub-
compartments defined by the epithelial and nuclear masks for each individual 
normal and tumoral cores was detected and quantified by the Visiomorph software. 
The detection is performed on each core (core1) and on the independent duplicate 
core (core2) associated with the same clinical sample.  Reproducibility of the 
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stainings within the same tissue is assessed by plotting values of MFI obtained by 
Visiomorph for core 1 on the X axis and the value of core 2 on the Y axis.  
B- Results for the quality-control analysis. Two-fold outliers values on plot presented 
in A were identified and cores were visually inspected and disregarded from the 
final analysis if they presented obvious aberrations (the results of this quality control 
analysis are presented for 53BP1, p-H2AX, RELA and p-CHK2).                          
The tables summarizes the number of core used and rejected (rejected cores vary 
from 0.2 to 1.6% of the total). 
 
Figure 5: Kaplan–Meier PSA recurrence-free survival and bone metastasis free 
curves in patients with prostate cancer for specific DDR signals   
Kaplan-Meier curves were plotted for all antibodies (not all data shown) for 
biochemical recurrence and bone metastasis.   
A- Nuclear-Epithelial pCHK2 in normal tissues.   
B- Nuclear-Stromal pCHK2 in normal tissues 
C- Nuclear-Epithelial p65 in normal tissues 
D- Nuclear-Epithelial pCHK2 in tumoral tissues 
E- Nuclear-Epithelial 53BP1 in tumoral tissues 
F- Nuclear-Stromal 53BP1 in tumoral tissues 
p = Significance value as indicated on bottom right corner of each graph. 
N = number of patients 
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 Figure S1 
A- Schematic representation of the TMA-cell approach for irradiated cells:  
1) Normal fibroblasts cells (BJ-u) were left untreated or irradiated with 10 Gy X-Ray 
and let recover for the indicated time periods.   
2) Cells were then trypsinized to obtain formalin-fixed cell pellets in histogel.   
3) Fixed histogel cell pellets were later embedded paraffin blocks and 
3-4) Cylindrical cores were extracted from individual paraffin blocks using a hollow 
needle and deposited into a recipient TMA paraffin block in an arrayed fashion.   
5) Slides are then sectioned for further immunofluorescence staining.   
6) The same process can be performed but with human tissue with up to 300 cores on 
one slide 
 
B- Map of the TMA-cell and representative full-core immunofluorescence images 
53BP1-red; p-H2AX-green; nucleus-blue DAPI 
 
C- Software mediated entire core detection and nucleus identification 
An entire core (top panel) stained by immunofluorescence as in B is detected by 
automated software analysis and detected nuclei are highlighted in pink over the blue  
color (lower panel).  
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Figure S2: Multicolor immunofluorescence staining in whole prostate cancer 
TMA  
Representative mosaic 20-X scan of an entire TMA representing 100 patients each with 
a normal core and a tumoral core (For a total of 200 cores, 20X magnification).  This 
slide was stained for immunofluorescence using DAPI (blue nuclei) and 
CK18/CK19/PSA (orange epithelium) as well as antibodies of interest to detect DDR 
activity, in this case, p-H2AX (green) and 53BP1 (red). 
 
 
Figure S3: Software quantification of immunofluorescence-detected DDR activity 
in paraffin embedded cells (magnified sections from cores in Figure 3) 
Nuclear signals are easier to visualize on magnified (zoomed) sections from cores 
shown in figure 3 in gray scale. 
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Table Legends 
 
Table 1:  Terry Fox Research Institute (TFRI) TMA of prostate cancer patient 
cohort. 
After TMA construction, patients were excluded from analysis based on pre-operative 
treatments (patients who had received hormonal therapy).  Mortality represents the 
number of prostate cancer specific deaths compared to all deaths.  Missing are 
parameters whose values were not available.   
 
Table 2: Univariate and multivariate cox regression analysis for                         
A) Biochemical failure and B) Bone metastasis  
Prognostic factors predicting PSA relapse and bone metastasis in prostate cancer cohort.          
Cox regression models and Hazard ratio are indicated.  RELA and 53BP1 nuclear MFI 
signals were used. 
Significant (p < 0.05) results indicated in bold. 
 
Table 3: Pearson Correlation (2-tailed) between nuclear DDR activity and clinico-
pathological parameters.   
Prognostic factors predicting PSA relapse and bone metastasis in prostate cancer cohort.   
Pearson correlations were considered significant at a p < 0.05 and is indicated by bold 
values.   
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Table 4:  Paired Sample T test for DDR markers between adjacent normal and 
tumor cells.   
Paired T-test evaluating expression differences of nuclear DDR markers between 
adjacent normal and tumor cells (as shown by sets of patients for each individual 
marker and as well as for the epithelial and stromal compartment). 
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MERGE OF FOUR COLOURS 
Figure 2: Multicolor immunofluorescence and mask segmentationanalysis in PCa 
TMA core  
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Figure 3: Software-based quantification of immunofluorescence-detected 
DDR activity in paraffin embedded cells	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1) MFI of 53BP1 in total nuclear-epithelium of normal cores 
2) MFI of 53BP1 in total nuclear-epithelium of tumoral cores 
Figure 4: Quality Control of DDR data on duplicate samples for Pca TMA 
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3) MFI of 53BP1 in total nuclear-stroma of normal cores 
4) MFI of 53BP1 in total nuclear-stroma of tumoral cores 
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A	  
Figure 5: Kaplan–Meier PSA recurrence-free survival and bone metastasis 
free curves in patients with PCa for specific DDR signals.  
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Schematic representation of the TMA-test approach for irradiated cells 
Map of the TMA-test and representative full-core 
Immunofluorescence images 
 
Software mediated 
entire core detection 
and nucleus 
identification 
Abbreviations: Ctrl = Control (non irradiated); 
0.5h-2h-8h-24h-10 days =  Timing of recovery 
following irradiation of 10 Gy; h= hours  
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TMA – Terry Fox 1 Figure S2: Multicolor immunofluorescence staining in whole Pca TMA  
DAPI, CK18-19-PSA, p-H2AX, 53BP1 
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Control	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Figure S3: Software quantification of immunofluorescence-detected DDR 
activity in paraffin embedded cells (magnified sections from cores in Figure 3)  
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Table 1: Terry Fox TMA of prostate cancer (Pca) patient cohort 
N= 288 
Age at diagnosis 
Mean 62.5 years 
Median 63 years 
Follow-up 
Average 101.5 months 
Median 100.5 months 
Gleason Score 
≤ 6 141 
7 118 
> 7 29 
PSA 
≤ 10 ng/mL 209 
10-20 ng/mL 65 
> 20 ng/mL 13 
 
pT stage 
2 209 
3 79 
  Surgical margins 
Negative 180 
Positive 98 
BCR 
Absent 178 
Present 110 
CRPC 
Absent 268 
Present 20 
Bone Metastasis 
Absent 269 
Present 19 
PCa Death 
Negative 276 
Positive 12 
LNI 
Absent 204 
Present 11 
SVI 
Absent 244 
Present 34 
ECE 
Absent 185 
Present 84 
AbbreviaOons:	  PSA	  =	  ProstaOc	  Speciﬁc	  AnOgen;	  pT:	  pathological	  T	  stage,	  	  
BCR:	  Biochemical	  recurrence;	  CRPC:	  Castrate	  resistant	  prostate	  cancer,	  Pca:	  
Prostate	  cancer,	  	  =	  Lymph	  node	  Invasion,	  SVI	  =	  Seminal	  Vesicle	  Invasion,	  
ECE	  =	  Extracapsular	  extension	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Table 2: Univariate and multivariate cox regression analysis for                         
A) biochemical failure and B) Bone metastasis  
	  
A	  
B	  
Abbrevia<ons:	  PSA	  =	  Prostate	  Speciﬁc	  AnOgen,	  GS	  =	  Gleason	  Score,	  SVI	  =	  Seminal	  Vesicle	  Invasion,	  ECE	  =	  
Extracapsular	  extension,	  NE_p65	  =	  Mean	  Fluorescent	  Intensity	  of	  p65	  in	  the	  epithelium	  of	  normal	  cores,	  
TE_53BP1	  =	  Mean	  Fluorescent	  Intensity	  of	  53BP1	  in	  the	  epithelium	  of	  tumoral	  cores,	  TS_53BP1	  =	  Mean	  
Fluorescent	  Intensity	  of	  53BP1	  in	  the	  stroma	  of	  tumoral	  cores,	  
!
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Table 2: Univariate and multivariate cox regression analysis for A) biochemical 
failure and B) Bone metastasis  
 
Factor Univariate Multivariate 
 HR 95% CI p HR 95% CI p 
PSA 1.031 1.013-1.049 0.001 1.018 0.994-1.044 0.142 
GS 1.837 1.528-2.208 0.000 1.431 1.161-1.764 0.001 
Margins 3.256 2.21-4.797 0.000 2.116 1.31-3.417 0.002 
SVI 4.872 3.134-7.576 0.000 1.682 0.967-2.925 0.066 
ECE 3.891 2.643-5.728 0.000 1.833 1.088-3.089 0.023 
NE_p65 1.001 1.000-1.002 0.029 1.001 1.000-1.002 0.005 
 
Factor Univariate Multivariate (TE_53BP1) Multivariate (TS_53BP1)!
 HR 95% CI p HR 95% CI p HR! 95% CI! p!
PSA 1.028 0.98-1.078 0.255 0.98 0.889-1.081 0.688 0.974! 0.889-1.068! 0.579!
GS 2.708 1.791-4.094 0.000 2.27 1.374-3.75 0.001 2.142! 1.293(3.546! 0.003$
Margins 2.484 0.979-6.30 0.055 0.977 0.349-2.739 0.965 0.894! 0.313(2.552! 0.834!
SVI 10.104 4.082-25.01 0.000 2.977 0.771-11.498 0.114 3.842! 1.045(14.131! 0.043!
ECE 4.713 1.768-12.564 0.002 1.407 0.329-6.016 0.645 1.458! 0.331(6.413! 0.618!
TE_53BP1 1.002 1.00-1.003 0.009 1.002 1.000-1.003 0.046 ! ! !
TS_53BP1 1.004 1.002-1.006 0.000    1.004! 1.001(1.007! 0.003$
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failure and B) Bone metastasis  
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Table 3: Pearson Correlation (2-tailed) between DDR activity and clinico-
pathological parameters.  
Abbreviations: Age Dx = patient’s age at diagnosis, PSA = Prostatic specific antigen,            
GS = Gleason score, LNI = Lymph node invasion 
SVI = seminal vesicle invasion, ECE = extracapsular extension, CRPC = castrate 
resistant prostate cancer, pTNM = pathologic stage, BCR = biochemical recurrence, 
Bone mets = Bone metastasis 
NE = Epithelium in the normal core, TE = Epithelium in the tumoral core, NS = 
Stroma in the normal core , TS = Stroma in the tumoral core  
Statistical significance ( p < 0.05) indicated in bold. 
	   NE_Chk2	   TE_Chk2	   NS_Chk2	   TS_Chk2	   NE_p65	   TE_p65	   NS_p65	   TS_p65	  
Age	  Dx	   0.066	   0.032	   0.037	   0.005	   0.029	   0.055	   0.046	   0.134	  
PSA	   -­‐0.041	   -­‐0.013	   -­‐0.034	   0.01	   -­‐0.004	   0.081	   0.005	   0.151	  
GS	   -­‐0.063	   -­‐0.181	   -­‐0.018	   -­‐0.123	   -­‐0.043	   -­‐0.153	   -­‐0.102	   -­‐0.121	  
LNI	   0.182	   0.111	   -­‐0.014	   0.215	   0.091	   0.026	   0.021	   -­‐0.005	  
SVI	   -­‐0.025	   -­‐0.121	   -­‐0.079	   -­‐0.089	   0.011	   -­‐0.016	   -­‐0.064	   0.048	  
ECE	   -­‐0.052	   -­‐0.066	   -­‐0.08	   -­‐0.007	   0.029	   -­‐0.051	   -­‐0.023	   0.036	  
Margins	   -­‐0.062	   -­‐0.013	   -­‐0.055	   0.018	   -­‐0.052	   -­‐0.083	   -­‐0.037	   0.013	  
CRPC	   0.062	   0.05	   -­‐0.006	   0.065	   0.037	   -­‐0.024	   -­‐0.012	   0.003	  
pTNM	   -­‐0.018	   -­‐0.021	   -­‐0.08	   0.014	   0.069	   -­‐0.005	   0.023	   0.071	  
BCR	   0.087	   0.021	   -­‐0.094	   0.036	   0.14	   -­‐0.013	   0.034	   0.054	  
Bone	  Mets	   0.092	   0.057	   -­‐0.017	   0.079	   0.014	   -­‐0.042	   -­‐0.032	   -­‐0.046	  
Survival	   0.071	   0.004	   -­‐0.037	   0.054	   0.022	   -­‐0.037	   -­‐0.039	   -­‐0.032	  
	  	   NE_53BP1	   TE_53BP1	   NS_53BP1	   TS_53BP1	   NE_H2AX	   TE_H2AX	   NS_H2AX	   TS_H2AX	  
Age	  Dx	   -­‐0.031	   0.021	   -­‐0.067	   0.035	   0.016	   -­‐0.047	   0.015	   0.027	  
PSA	   -­‐0.025	   -­‐0.061	   0.032	   0.05	   0.025	   0.007	   0.056	   0.087	  
GS	   -­‐0.032	   0.036	   0.115	   0.025	   0.019	   -­‐0.038	   -­‐0.082	   -­‐0.102	  
LNI	   -­‐0.014	   -­‐0.01	   -­‐0.009	   0.021	   0.02	   -­‐0.037	   0.037	   -­‐0.09	  
SVI	   0.055	   0.17	   0.125	   0.067	   -­‐0.049	   -­‐0.071	   -­‐0.072	   -­‐0.036	  
ECE	   0.076	   0.107	   0.046	   -­‐0.02	   0.013	   -­‐0.108	   0.003	   -­‐0.043	  
Margins	   -­‐0.026	   0.041	   -­‐0.001	   -­‐0.031	   -­‐0.017	   -­‐0.058	   -­‐0.036	   0.014	  
CRPC	   -­‐0.006	   0.052	   -­‐0.027	   0.186	   0.002	   0.071	   -­‐0.064	   -­‐0.014	  
pTNM	   0.068	   0.165	   0.016	   0.032	   0.031	   -­‐0.096	   0.045	   -­‐0.034	  
BCR	   0.061	   0.035	   0.059	   -­‐0.044	   0.108	   0.044	   0.071	   0.057	  
Bone	  Mets	   0.015	   0.143	   0.04	   0.203	   -­‐0.048	   0.034	   -­‐0.081	   -­‐0.079	  
Survival	   0.045	   0.14	   0.05	   0.188	   -­‐0.034	   0.091	   -­‐0.06	   -­‐0.016	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Table 4: Paired Sample T test for DDR markers between adjacent normal and 
tumoral cells.  
Abbreviations: MFI = Mean Fluorescence Intensity, NE = Epithelium in the 
normal core, TE = Epithelium in the tumoral core, NS = Stroma in the normal 
core , TS = Stroma in the tumoral core  
Statistical significance ( p < 0.05) indicated in bold. 
 
 
Paired Samples Test 
 
Paired Differences 
t df Sig. (2-tailed) 
Mean 
MFI of 
total 
cohort 
Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
NE_Chk2 
TE_Chk2 
841.12 
832.85 
41.881 2.512 3.318 13.207 3.289 277 0.001 
Pair 2 
NS_Chk2 
TS_Chk2 
840.97 
842.76 
71.156 4.268 -10.185 6.617 -.418 277 0.676 
Pair 3 
NE_p65 
TE_p65 
636.62 
607.8 
174.633 10.474 8.202 49.438 2.752 277 0.006 
Pair 4 
NS_p65 
TS_p65 
754.54 
686.16 
190.399 11.419 45.894 90.854 5.988 277 0.000 
Pair 5 
NE_53BP1 
TE_53BP1 
1517.0 
1683.13 
351.777 21.136 -207.735 -124.518 -7.860 276 0.000 
Pair 6 
NS_53BP1 
TS_53BP1 
1176.87 
1185.63 
196.041 11.779 -31.950 14.426 -.744 276 0.458 
Pair 7 
NE_pH2AX 
TE_pH2AX 
1232.54 
1095.50 
372.367 22.414 92.915 181.164 6.114 275 0.000 
Pair 8 
NS_pH2AX 
TS_pH2AX 
1557.98 
1319.48 
452.697 27.249 184.857 292.143 8.753 275 0.000 
 !
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CHAPTER 3: DISCUSSION  
1.0 The DDR as a cancer barrier 
In order to preserve genome integrity, cells need to protect themselves against a huge 
number of DNA lesions per day, particularly against DSBs, which are the most lethal 
type of DNA damage.  Once cells detect DNA breaks, the DDR is initiated, this 
acrivation is required to stop the proliferation of cells with genomic instability, and 
therefore, prevent cancer progression.  Other than cancer, cells defective in these 
mechanisms can also cause other human diseases such as neurodegenerative disorders 
including ataxias, Fanconi anaemia, infertility and other more diseases151.  DDR leads 
to temporary cell cycle arrest and DNA repair, apoptosis, or senescence, preventing 
cells to replicate with accumulated mutations.  The DDR is a central tumor suppression 
mechanism in mammals, and the loss of DDR genes such as the tumor suppressor p53 
is always implicated in cancer progression.  Importantly for cancer treatment, DSBs 
can result from ionizing radiation.  Thus, the DDR determines how normal and cancer 
cells react to DNA damaging agents used for cancer therapy (radiation therapy and 
chemotherapy).  We wanted to refine our understanding of DDR signalling during 
cancer progression or treatment and to further characterize this DDR activity in human 
prostate cancer.   
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1.1  DDR activity: a cancer barrier in prostate cancer   
We elected to characterize DDR activity in human prostate cancer, which is a 
particularly promising model.  In addition to the preliminary data describing DDR 
activation during prostate cancer progression104, DDR activity has been detected in 
prostate cancer tumors following chemotherapy150.  Additional studies have established 
that a DDR-mediated barrier restrict early-stage prostate cancer progression in a mouse 
model (p53-mediated senescence in prostate specific PTEN-deficiency)106; 107.  This 
senescence barrier occurs at a stage equivalent to HG-PIN in humans and is consistent 
with the loss of the tumor suppressor PTEN relaxes PI3-K/AKT-dependant 
proliferation inhibition. This results in genomic instability and persistent DDR 
signalling108.  Further supporting this senescence barrier, short telomeres (known to 
directly trigger the DDR) have been observed in human HG-PIN109.  Together, these 
lines of evidence strongly suggest that the p53-mediated senescence barrier during HG-
PIN could be partially driven by DDR signalling.  Although, there is evidence of 
increasing DDR activity from the normal to the preneoplasic state 104, little is known on 
DDR activity during cancer progression beyond the pre-neoplastic stages.  These 
observations suggest that during its evolution, cancer cells need to stabilize their 
genomes to become even more aggressive by surpassing this DDR barrier.   
 
In our study, we found a low level of DDR activity in adenocarcinoma as compared to 
normal cells in our cohort of prostate cancer patients.  Furthermore, within those lower 
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levels, patients with lowest levels could have a better prognosis.  These findings can be 
explained by the concept of cancer immunoediting.  At first, as it has already been 
shown, ATM is activated in earlier stages of prostate tumorigenesis (PINs) leading to 
an increased level of DDR.  These pre-neoplastic cells are then eliminated by the 
immune system leading to the secretion of pro-inflammatory signals and recruitment of 
immune cells such as T-lymphocytes and natural killer cells resulting in the 
suppression of these pre-neoplasic cells.  Following this process, equilibrium settles 
after an incomplete destruction of the tumor cells.  After genetic instability, 
adenocarcinoma develops.  The growth of tumor cells have survived the pressure of the 
immune system and prostatic cells have probably only stabilized their genome when 
becoming adenocarcinoma cells. 
Moreover, a recent study has pointed out that prostate cancer progression is associated 
with an expansion of regulatory T cells that could down-regulate tumour immune 
surveillance 152.   
 
2.0  Repair Mechanisms   
DDR is initiated to stop the proliferation of cells with genomic instability.  DDR will 
lead to different cell fate including DNA repair.  Two distinct pathways have evolved 
to eliminate DSBs: nonhomologous DNA end joining (NHEJ) and homologous 
recombination (HR).  The HR requires that cells be in the S or G2 phase of the cell 
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cycle, when DNA replication generates the sister chromatid to direct the repair process.  
HR is a type of genetic recombination in which sequences of nucleotides are 
exchanged between two similar or identical molecules of DNA sequences elsewhere in 
the genome to serve as templates for DNA repair in order for the damaged molecule to 
return to the their initial form, before the DSB.. HR has a role in preserving the 
genome’s integrity as well as a role in faithfully duplicating the genome by providing 
critical support for DNA replication and telomere maintenance.  NHEJ occurs in all 
phases of the cell cycle, and is thus neither phase specific nor cycle specific.  NHEJ is a 
more rapid process than HR but less accurate, with small deletions or insertions often 
resulting at the repaired break site.  The main steps in NHEJ, after sensing the DSB, 
involve nucleases to remove damaged DNA, polymerases to help repair and ligases to 
restore the continuity of the DNA chain.  The first event starts with the binding of two 
proteins (Ku70 and Ku80) to the DNA ends which occurs within seconds of the break.  
This binding serves to protect ends from degradation by exonucleases as well as to 
recruit DNA-PKcs.  This large protein forms a physical bridge between the two ends, 
helping to keep them in close proximity for subsequent repair events.  DNA-PKcs also 
phosphorylates a number of target proteins involved in checkpoints and repair..  
Making the choice between which pathway (HR and NHEJ) is used has been 
extensively studied36.   We will focus on the HR where the 53BP1 protein has a major 
role.   
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2.1  53BP1 and Homologous Recombination  
In addition to its role in HR, 53BP1 is a central component of chromatin-based DSB 
signalling.  53BP1 is a large protein of 1972 amino acids that has no apparent 
enzymatic activity but contains interaction surfaces for numerous DSB-responsive 
proteins.  Important structural elements in 53BP1 include the breast cancer 1 (BRCA1) 
carboxy-terminal (BRCT) repeats, the tandem Tudor domains and 28 amino-terminal 
Ser/Thr-Gln (S/T-Q) sites, which are phosphorylated, at least in part, by ATM kinase 
153.  Loss of 53BP1 or its failure to localize to damaged chromatin significantly reduces 
the phosphorylation of ATM targets such as p53, CHK2 and BRCA1 and, as a 
consequence, leads to G2–M checkpoint defects and genomic instability.  Upon entry 
into S phase, BRCA1 helps to switch the mode of DSB repair by excluding 53BP1–
RIF1 complexes from the DSB, thus enabling extensive DSB resection and the 
initiation of HR154.   
Although the mechanisms are not completely understood, it is known that in humans, 
mutations in the BRCA1 gene increase the risk of breast and ovarian cancers by 
impairing HR.  It has been demonstrated that when 53BP1 is defective, formation of 
the mammary tumors that normally develop in BRCA1 mutant mice was suppressed155.  
Mouse BRCA1-associated mammary tumors have significant similarities to human 
BRCA1-associated breast cancer in regard to tumor aggressiveness, high incidence, 
mutations, and genetic instability.  Furthermore, the team found that inactivation of 
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53BP1 restored the DNA repair function that is lost when BRCA1 is mutated. The same 
group also discovered that both BRCA1 and 53BP1 are capable of binding to 
replication-associated chromosome breaks; so when both proteins are present, BRCA1 
displaces 53BP1, the HR machinery has full access to the breaks, and HR proceeds.  In 
BRCA1-deficient cells, the binding of 53BP1 to the site of DNA damage interferes with 
the DNA repair activity of HR proteins, so an alternative pathway that is more prone to 
produce mutations repairs the damage instead.  When 53BP1 is absent, BRCA1 is not 
needed to displace it so HR can take place normally.   
Our study shows that a lower level of 53BP1 protein expression in tissue is associated 
with a better prognosis and it might be similarly explained by the restoration of the 
DNA repair.  Alternatively, since this event occurs in cancer cells, it is possible that 
altered 53BP1 levels modulate other non-DNA repair related cell functions important 
for bone metastasis.  To further explain these findings, our group may also evaluate the 
presence or absence of BRCAs mutations in our cohort of patients.  
 
3.0  Why do we need biomarkers?  
Treatment options for localized prostate cancer in 2014 are mainly radiation therapy or 
surgery.  Both have shown similar survival outcomes in low and intermediate risk 
prostate cancer patients.  Contemporary radiotherapy approaches such as intensity-
modulated radiation therapy (IMRT) have permitted increased delivery of radiation to 
the prostate while sparing adjacent organs, reducing the potential for acute and chronic 
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toxicity.  However, proctitis, cystitis, and erectile dysfunction remain significant 
complications of high-dose radiotherapy.  In turn, local failure after radiotherapy 
remains 20%–35% in intermediate and high-risk patients, leading to increased 
metastasis and lower survival.  Hormonal therapy has proven value when combined 
with localized radiotherapy in intermediate and high risk prostate cancer patients, but 
carries its own set of morbidities, including increased cardiovascular and 
thromboembolic risk.  In daily clinical setting, it is difficult for a clinician to orient a 
patient towards one type of treatment over another since radiotherapy and surgery both 
gives very good results based on the available literature.  If the clinician could know, 
based on a biomarker, which patient will have a better response to one type of therapy 
(ie: radiation compared to surgery if this particular patient has a more radiosensitive 
tumor as compared to another patient), the patient will receive the more efficient 
treatment.  Furthermore, the use of novel agents with more attractive side effect 
profiles that can be combined with radiotherapy to improve local control in high-risk 
patients and/or permit a dose reduction in lower-risk patients would be of great value.   
 
3.1 DDR activity as a biomarker   
The DDR is responsible for maintaining genome stability and we hypothesize that 
basal level of DDR in cancer prior to treatment has the potential to influence how the 
cancer cells will react to treatment.  Current data suggest that the modified chromatin 
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foci at the sites of persistent DNA breaks serve to promote the tumour suppressor 
senescence arrest32;157.  Alternatively, defects in the DDR regulators and tumor 
suppressor pathways p53 and/or Rb are common in cancer and may allow tumor cells 
to maintain genomic instability and tolerate persistent DNA damage, by blocking 
senescent signalling while promoting cell proliferation and survival.  In senescent cells 
or cancer cells that tolerate damage, the presence of P-H2AX and 53BP1 localization 
to DNA damage foci can serve as proxies for unrepaired DSBs and the DNA damage 
response158; 159. 
These DDR markers that can be accurately and quantitatively assessed could help 
define a strategy and novel biomarkers to predict treatment outcomes and adapt 
treatment strategy.  For example, hormonal therapy may be used for intermediate risk 
cancer patient with a bad prognosis based on DDR activity.  Another example is 
following patients presenting with PIN on their prostate biopsy under a strict 
surveillance protocol in order to detect prostate adenocarcinoma in early stages.  
Finally, these findings could help design targeted sensitization of prostate cancer cells 
to DNA damaging agent used in therapy including ionizing radiation.  
Because the DDR controls cellular responses that are absolutely essential to 
radiotherapy treatment outcomes, biochemical components of this signalling cascade 
become potential pharmaceutical targets for treatment optimization.  
Alternatively, gaining information about the initial “DDR state” of the tumor could 
help predict whether a particular cancer will respond well to DNA damaging agents 
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during treatment.  Finding new biomarkers predicting what kind of DDR cells/tumors 
mount against radiotherapy will have the potential to improve treatment selection and 
success.  Currently, the exact regulation and outcomes of DDR signalling in cancer 
cells remain relatively unknown.  
Following our findings, we could try to identify if our cohort of patients are BRCA1 
deficient and could eventually be more sensitive to RT.  Furthermore, because tumor 
cells that are BRCA1-deficient are driven to turn to other, less faithful DNA repair 
pathways and they may become resistant to chemotherapy/RT by acquiring additional 
mutations.  
 
4.0 DDR activity in our cohort of patients   
Despite the apparent increase in the incidence of prostate cancer in the 1970-80s 
mostly caused by increased use of TURP for treating BPH resulting in the increased 
incidental detection of preclinical cases (as well as increased PSA testing), very good 
biochemical control and decline in mortality has been noted.  Nevertheless, bone 
metastases are common in advanced prostate cancer, occurring in up to 75 % of 
patients with advanced cancer160  and it is much less frequent in less advanced patients.  
Our cohort of 288 evaluated patients consisted mostly of low risk patients with only 29 
patients with Gleason > 7 and 79 patients with PSA > 10 ng/mL which could explain 
the low number of bone metastases (19/288).  Although the average follow up of 101.5 
months is quite long, the fact that prostate cancer patients have very good prognosis 
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and show bone metastasis many years following their initial radical prostatectomy, 
might explain this low number of events.  Nonetheless, we did find a statistical 
significant relation between two of the evaluated DDR markers and outcome (BCR and 
bone metastasis).  This study validates a prior finding that p65 correlates with prostate 
cancer prognosis.  In this context, our group has already address the prognostic value 
of the p65 subunit of Nuclear Factor -κB in prostate cancer58.  In this context the 
implication of NF-κB p65 in cancer progression has been extensively studied.  The 
frequency of p65 nuclear distribution in prostatic tumor cells has been reported to 
correlate with Gleason score and the presence of lymph node metastasis58;161.  
Moreover, the presence of nuclear p65 in radical prostatectomy tissues predicts BCR in 
prostate cancer patients59; 162; 163.   
As for 53BP1, this study is, to our knowledge, the first to show a correlation with 
patient’s prognosis.  Indeed, in our cohort of patients, those expressing a lower level of 
53BP1 in the nuclei of the tumor and adjacent stroma or epithelium had a lower chance 
of developing bone metastasis.   
We suspect more results pertaining to DDR markers and biochemical control, bone 
metastases as well as prostate cancer survival will be obtained with longer follow-up of 
our cohort as the biobank continue to mature with more clinical data.   
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5.0  Limitations of our study   
5.1 Validation study on TMA-cell and TMA-tissue 
Throughout our research project, we have encountered a few challenging aspects.  
Firstly, our antibodies have been optimized on fibroblasts (TMA-cell) where DNA 
damage has been voluntary induced by irradiation so that the DDR markers could be 
easily evaluated.  However, DDR markers were more difficult to evaluate on human 
tissue (TMA-tissue and TMA-TFRI).  This can be explained by the fact that blocks 
used were constructed from specimens obtained by the surgeon who were then placed 
in formalin and processed by the pathology department, processes out of our control.  
Furthermore, the TMA-TFRI has been built almost 5 years ago and recognition of the 
different epitopes may have been altered with time.  This is perhaps particularly 
important for epitopes with sensitive modifications such as phosphorylation.  In order 
to ensure that our methods were as reliable as possible, the TMA-cell which was built 
under our control and which showed an excellent recognition of investigated DDR 
signals, was used as a control in all our experiments.  
 
5.2 Data quality control  
Quality control on our data had to be done to validate our data.  The TMA-TFRI was 
constructed in a manner where each patient had replicates of their tumor tissue core as 
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well as of normal tissue cores.  For example, patient X had a core of tumoral tissue and 
normal tissue on two separate slides (TF-1Aand TF-1B).  Since those cores were taken 
from different areas in the tumor and normal tissue of the same patient, we had to go 
visually inspect each of the cores to eliminate the cores that were aberrant (damaged 
core, external source of artifact or unexplained cause).  This quality control was 
performed to make sure the results obtained were due to tumor/tissue biology rather to 
a human factor.  
 
5.3  Immunofluorescence technique 
We mainly used IF in our experiments to detect protein expression.  Although this 
technique has numerous advantages, it has a few limitations.  IF detects more than one 
protein at a time and it can examine the co-localization of two antigens in the same 
subcellular compartment.  It has therefore the capability for multiple labeling and has a 
higher resolution due to the fluorophores directly conjugated to the antibody.  
However, when IF is used on FFPE tissues, inherent autofluorescence of such 
specimens makes high quality immunofluorescence sometimes more difficult. 
Fortunately, although we did find autofluorescence in our TMA-cell, we have 
succeeded to optimize our antibodies and reduce this autofluorecence.  Similarly, 
quantitative IF labeling of FFPE material, particularly that in TMA, has been achieved 
by the development of computer assisted fluorescence imaging systems164.   
Moreover, our group has optimized a method consisting of careful microscopy 
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practices and use of the analysis software to reliably detect protein expression of 
multiple markers in different compartments of FFPE human tissue.  
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Conclusion 
DDR is a complex signalling network and its failure causes genomic instability, an 
underlying cause of cancer.   While prostate cancer is the most frequently diagnosed 
cancer in Canadian men and is the third deadliest cancer in males, treatments available 
including surgery, different types of radiation therapy and hormonal therapy are still 
offered based on the patient’s PSA, clinical stage and Gleason score.  The tumor 
biology of individual patient is still not taken into consideration for clinical 
management of men diagnosed with prostate cancer.  After creating a TMA-cell 
consisting of irradiated cells to induce DNA damage, we optimized 4 different 
antibodies that were validated on human tissue and then applied to a TMA of 300 
prostate cancer patients.  This was done by IF which has many advantages including 
the possibility to associate a fluorescent channel to an individual mask such as the 
nucleus, epithelium and at least two DDR markers at a time.  DDR signals (fluorescent 
staining) obtained on the TMAs were quantified by a software which is more robust 
(reproducible, unbiased and versatile) than a person’s visual scoring.  DDR marker 
53BP1 and p65 seem to have prognostic value in patients with prostate 
adenocarcinoma.  Patients expressing reduced amounts of 53BP1 have a better bone 
metastasis free survival (p=0.005) and those with reduced amounts of p65 have a better 
biochemical control (p=0.002).   These findings were also correlated in univariate and 
multivariate cox regression analyses.  Validation of other DDR markers as they 
become available may also correlate with patients’ outcome.  Since prostate cancer 
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patients have very good prognosis and relapse much later than other types of cancers 
(ex-ovarian cancers), a longer follow-up may translate into correlation with survival. 
 
Perspectives 
The prostate TMAs used in this study consisted of samples from patients who 
exclusively underwent radical prostatectomy.  These samples are useful to determine 
whether DDR activation in the original tumors correlates with treatment outcome.  
Upon further optimization of further DDR markers as evaluated here, our long-term 
objective is to broaden our views of how DDR signalling is regulated during prostate 
cancer progression and to provide information about potential genetic targets that could 
be used as predictive biomarkers.  Therapy by ionizing radiation, already widely 
accepted as a treatment for prostate cancer, may be improved by rendering prostate 
cancer cells more sensitive to irradiation and protecting normal rectal and bladder cells, 
the organs considered at risk when treating a prostate by irradiation.  We would like to 
construct a new TMA based on an ideal cohort for DNA damage and DDR activity 
evaluation.  We plan to collect prospective samples of prostate cancer from all prostate 
risk categories (ie: NCCN low-intermediate and high risk) patients treated with 
external beam radiation including samples obtained following radiation treatment 
through biopsies.  Patients who will have chosen radiation treatment will have their 
tissues collected at diagnosis (at the time of biopsy) where PIN samples (if existing 
within the specimen) will also be included, at 1 month post radiation as well as at six 
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months post irradiation.  This would be considered ideal since ionizing radiation 
directly affects DDR and we would be looking at DDR markers in patients receiving 
DNA damage.  This could help define a strategy to predict treatment outcomes and 
define priority targets to sensitize prostate cancer cells to DNA damaging agents 
including ionizing radiation.  This will be done to gather prospective preliminary 
results of the immediate DDR response to irradiation (in prostate cancer cells), and 
eventually to correlate this DDR response to treatment outcomes as our biobank mature 
and accumulate patient’s clinical outcome data.  
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